<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2300102-B1" country="EP" doc-number="2300102" kind="B1" date="20140108" family-id="41258402" file-reference-id="318268" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146588655" ucid="EP-2300102-B1"><document-id><country>EP</country><doc-number>2300102</doc-number><kind>B1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-09747707-A" is-representative="NO"><document-id mxw-id="PAPP154850847" load-source="docdb" format="epo"><country>EP</country><doc-number>09747707</doc-number><kind>A</kind><date>20090515</date><lang>EN</lang></document-id><document-id mxw-id="PAPP194231238" load-source="docdb" format="original"><country>EP</country><doc-number>09747707.9</doc-number><date>20090515</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140554119" ucid="US-2009044192-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2009044192</doc-number><kind>W</kind><date>20090515</date></document-id></priority-claim><priority-claim mxw-id="PPC140548296" ucid="US-5360508-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>5360508</doc-number><kind>P</kind><date>20080515</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130729</date></intention-to-grant-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989326252" load-source="docdb">A61K  39/00        20060101ALI20130624BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989326253" load-source="docdb">A61K  31/7052      20060101ALI20130624BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989326254" load-source="docdb">A61P  37/08        20060101AFI20130624BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1987049729" load-source="docdb" scheme="CPC">A01K2267/0387      20130101 LA20151230BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987061980" load-source="docdb" scheme="CPC">A61K  31/7088      20130101 LI20151230BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987062500" load-source="docdb" scheme="CPC">A01K2207/10        20130101 LA20151230BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987063643" load-source="docdb" scheme="CPC">A01K  67/027       20130101 LI20151230BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987063798" load-source="docdb" scheme="CPC">A01K2227/105       20130101 LA20151230BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2107938467" load-source="docdb" scheme="CPC">A61K2039/57        20130101 LA20150122BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2107940940" load-source="docdb" scheme="CPC">A61K2039/55561     20130101 LA20150123BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2107944899" load-source="docdb" scheme="CPC">A61K2039/545       20130101 LA20150122BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2107946027" load-source="docdb" scheme="CPC">A61K  39/36        20130101 LI20150123BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2107946241" load-source="docdb" scheme="CPC">A61K  39/35        20130101 LI20150122BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2107953052" load-source="docdb" scheme="CPC">A61K  39/39        20130101 FI20150123BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132370598" lang="DE" load-source="patent-office">Immunstimulatorische Sequenzen enhaltend CpG zur Verwendung bei der Behandlung der allergischen Rhinitis</invention-title><invention-title mxw-id="PT132370599" lang="EN" load-source="patent-office">Immunostimulatory sequences containing CpG for use in the treatment of allergic rhinitis</invention-title><invention-title mxw-id="PT132370600" lang="FR" load-source="patent-office">Oligonucléotides immunostimulants comprenant CpG pour son utilisation dans le traitement de la rhinite allergique</invention-title><citations><non-patent-citations><nplcit><text>BROIDE D H ET AL: "Systemic administration of immunostimulatory DNA sequences mediates reversible inhibition of Th2 responses in a mouse model of asthma.", JOURNAL OF CLINICAL IMMUNOLOGY MAY 2001 LNKD- PUBMED:11403224, vol. 21, no. 3, May 2001 (2001-05-01), pages 175 - 182, ISSN: 0271-9142</text><sources><source mxw-id="PNPL67194514" load-source="docdb" name="EXA"/></sources></nplcit><nplcit><text>TIGHE H ET AL: "Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity.", THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY JUL 2000 LNKD- PUBMED:10887315, vol. 106, no. 1 Pt 1, July 2000 (2000-07-01), pages 124 - 134, ISSN: 0091-6749</text><sources><source mxw-id="PNPL67192998" load-source="docdb" name="EXA"/></sources></nplcit></non-patent-citations></citations></technical-data><parties><applicants><applicant mxw-id="PPAR919514278" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>DYNAVAX TECH CORP</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR919535805" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>DYNAVAX TECHNOLOGIES CORPORATION</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919538570" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>HESSEL EDITH M</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919511489" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>HESSEL, EDITH, M.</last-name></addressbook></inventor><inventor mxw-id="PPAR919024105" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>HESSEL, EDITH, M.</last-name><address><street>493 Alvarado Street</street><city>San Francisco CA 94114</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919527026" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>COFFMAN ROBERT L</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919533889" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>COFFMAN, ROBERT, L.</last-name></addressbook></inventor><inventor mxw-id="PPAR919024104" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>COFFMAN, ROBERT, L.</last-name><address><street>239 Echo Lane</street><city>Portola Valley CA 94028</city><country>US</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR919024106" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Dynavax Technologies Corporation</last-name><iid>100113510</iid><address><street>2929 Seventh Street, Suite 100</street><city>Berkeley, CA 94710</city><country>US</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR919024107" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Roques, Sarah Elizabeth</last-name><iid>101206731</iid><address><street>J A Kemp 14 South Square Gray's Inn</street><city>LONDON WC1R 5JJ</city><country>GB</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2009044192-W"><document-id><country>US</country><doc-number>2009044192</doc-number><kind>W</kind><date>20090515</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2009140626-A2"><document-id><country>WO</country><doc-number>2009140626</doc-number><kind>A2</kind><date>20091119</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549895220" load-source="docdb">AT</country><country mxw-id="DS549804678" load-source="docdb">BE</country><country mxw-id="DS549788940" load-source="docdb">BG</country><country mxw-id="DS549787620" load-source="docdb">CH</country><country mxw-id="DS549804679" load-source="docdb">CY</country><country mxw-id="DS549895229" load-source="docdb">CZ</country><country mxw-id="DS549924973" load-source="docdb">DE</country><country mxw-id="DS549804684" load-source="docdb">DK</country><country mxw-id="DS549804685" load-source="docdb">EE</country><country mxw-id="DS549878980" load-source="docdb">ES</country><country mxw-id="DS549788945" load-source="docdb">FI</country><country mxw-id="DS549787625" load-source="docdb">FR</country><country mxw-id="DS549924974" load-source="docdb">GB</country><country mxw-id="DS549804686" load-source="docdb">GR</country><country mxw-id="DS549924975" load-source="docdb">HR</country><country mxw-id="DS549895230" load-source="docdb">HU</country><country mxw-id="DS549787626" load-source="docdb">IE</country><country mxw-id="DS549804687" load-source="docdb">IS</country><country mxw-id="DS549788946" load-source="docdb">IT</country><country mxw-id="DS549804692" load-source="docdb">LI</country><country mxw-id="DS549788947" load-source="docdb">LT</country><country mxw-id="DS549882694" load-source="docdb">LU</country><country mxw-id="DS549788948" load-source="docdb">LV</country><country mxw-id="DS549788961" load-source="docdb">MC</country><country mxw-id="DS549882695" load-source="docdb">MK</country><country mxw-id="DS549882696" load-source="docdb">MT</country><country mxw-id="DS549878981" load-source="docdb">NL</country><country mxw-id="DS549872525" load-source="docdb">NO</country><country mxw-id="DS549878990" load-source="docdb">PL</country><country mxw-id="DS549788962" load-source="docdb">PT</country><country mxw-id="DS549895231" load-source="docdb">RO</country><country mxw-id="DS549878991" load-source="docdb">SE</country><country mxw-id="DS549787627" load-source="docdb">SI</country><country mxw-id="DS549872530" load-source="docdb">SK</country><country mxw-id="DS549882697" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><description mxw-id="PDES63961074" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001">FIELD OF THE INVENTION</heading><p id="p0001" num="0001">The invention relates to treating allergic rhinitis by using multiple administrations of one or more immunostimulatory sequences ("ISS") that confer long term disease modification.</p><heading id="h0002">BACKGROUND OF THE INVENTION</heading><p id="p0002" num="0002">The type of immune response generated by infection or other antigenic challenge can generally be distinguished by the subset of T helper (Th) cells involved in the response. The Th1 subset is responsible for classical cell-mediated functions such as delayed-type hypersensitivity and activation of cytotoxic T lymphocytes (CTLs), whereas the Th2 subset functions more effectively as a helper for B-cell activation. The type of immune response to an antigen is generally influenced by the cytokines produced by the cells responding to the antigen. Differences in the cytokines secreted by Th1 and Th2 cells are believed to reflect different biological functions of these two subsets. See, for example,<nplcit id="ncit0001" npl-type="s"><text> Romagnani (2000) Ann. Allergy Asthma Immunol., 85:9-18</text></nplcit><i>.</i></p><p id="p0003" num="0003">The Th1 subset may be particularly suited to respond to viral infections, intracellular pathogens, and tumor cells because it secretes IL-2 and IFN-γ, which activate CTLs. The Th2 subset may be more suited to respond to free-living bacteria and helminthic parasites and may mediate allergic reactions, since IL-4 and IL-5 are known to induce IgE production and eosinophil activation, respectively. In general, Th1 and Th2 cells secrete distinct patterns of cytokines and so one type of response can moderate the activity of the other type of response. A shift in the Th1/Th2 balance can result in an allergic response, for example, or, alternatively, in an increased CTL response.<!-- EPO <DP n="2"> --></p><p id="p0004" num="0004">It has been recognized for some time that a Th1-type immune response can be induced in mammals by administration of certain ISSs. The ISSs include sequences referred to as immunostimulatory sequences ("ISS"), often including a CG. See, e.g., <patcit id="pcit0001" dnum="WO9855495A"><text>PCT Publications WO 98/55495</text></patcit>, <patcit id="pcit0002" dnum="WO9728259A"><text>WO 97/28259</text></patcit>, <patcit id="pcit0003" dnum="US6194388B"><text>U.S. Pat. Nos. 6,194,388</text></patcit>; <patcit id="pcit0004" dnum="US6207646B"><text>6,207,646</text></patcit>, and <patcit id="pcit0005" dnum="US6498148B"><text>6,498,148</text></patcit>; and <nplcit id="ncit0002" npl-type="s"><text>Krieg et al. (1995) Nature, 374:546-49</text></nplcit>. For many infectious diseases, such as tuberculosis and malaria, Th2-type responses are of little protective value against infection. Protein-based vaccines typically induce Th2-type immune responses, characterized by high titers of neutralizing antibodies but without significant cell-mediated immunity. Moreover, some types of antibody responses are inappropriate in certain indications, most notably in allergy where an IgE antibody response can result in anaphylactic shock.</p><p id="p0005" num="0005">A treatment for allergic rhinitis that could confer long term benefits has not been well-characterized either. The invention disclosed herein provides teachings useful to address the foregoing.</p><heading id="h0003">BRIEF SUMMARY OF THE INVENTION</heading><p id="p0006" num="0006">In accordance with the present invention, there is provided an unconjugated immunostimulatory sequence (ISS) for use in a method for treating allergic rhinitis in an individual, wherein the ISS contains a CpG motif and wherein said method comprises administering to the individual at least 8 administrations of an effective amount of said ISS, wherein the ISS are administered at intervals of 3 to 14 days, and wherein the administration results in a long term disease modification of allergic rhinitis, by the reduction or elimination of one or more allergic rhinitis symptoms for a period of at least 13 weeks following administration of the last dose of ISS. In one embodiment, the disease modification is a suppression of Th2 immune response in the individual to whom the ISS was administered.</p><heading id="h0004">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p0007" num="0007"><ul><li><figref idrefs="f0001">Figure 1</figref> is a graph that depicts results for six genes ISS important for the development of a Th2-type airway inflammatory response when sensitized mice are challenged intranasally with ragweed. The data are expressed as gene/ubiquitin ratio.<!-- EPO <DP n="3"> --></li><li><figref idrefs="f0002">Figure 2</figref> is a graph that depicts inhibition of Th2 gene induction for GOB-5 and C2 by pretreatment with 1018 ISS. The data are expressed as gene/ubiquitin ratio.</li><li><figref idrefs="f0003">Figure 3</figref> is a graph that depicts levels of the Th2-type cytokines IL-4 and IL-13 detected in BAL fluid. The double asterisks indicate a statistical significance of p &lt; 0.01. The single asterisk indicates a statistical significance of p &lt; 0.05.</li><li><figref idrefs="f0004">Figure 4</figref> is a graph that depicts levels of the Th2-type cytokine IL-10 and Th1 type cytokine INF-γ detected in BAL fluid. The double asterisks indicate a statistical significance of p &lt; 0.01.</li><li><figref idrefs="f0005">Figure 5</figref> is a graph that depicts absolute number of eosinophils detected in BAL fluid. The double asterisks indicate a statistical significance of p &lt; 0.01.</li><li><figref idrefs="f0006">Figure 6</figref> is a graph that depicts levels of the Th2-type cytokines IL-4, IL-5, IL-10 and IL-13 measured in lavage fluid (BAL fluid) in mice that have been treated with multiple administrations of 1018 ISS.</li><li><figref idrefs="f0007">Figure 7</figref> is a graph that depicts levels of the Th2-type cytokines IL-4, IL-5, IL-10 and IL-13 measured in lavage fluid (BAL fluid) in mice that have been treated with multiple administrations of 1018 ISS or TOLAMBA.</li><li><figref idrefs="f0008">Figure 8</figref> is a graph that depicts results that show that re-sensitization with ragweed or ovalbumin does not lead to allergen-induced airway eosinophilia.</li><li><figref idrefs="f0009">Figure 9</figref> is a graph that depicts results that show that re-sensitization with ragweed or ovalbumin does not lead to allergen-induced elevated bal th2 cytokines.</li><li><figref idrefs="f0010">Figure 10</figref> is a graph that depicts results that show that presence of ova-specific IgE indicates successful system sensitization to ovalbumin.</li></ul></p><heading id="h0005">DETAILED DESCRIPTION OF THE INVENTION</heading><p id="p0008" num="0008">The invention herein provides an unconjugated immunostimulatory sequence (ISS) for use in a method for treating allergic rhinitis in an individual, wherein the ISS contains a CpG motif and wherein said method comprises administering to the individual at least 8 administrations of an effective amount of said ISS, wherein the ISS are administered at intervals of 3 to 14 days, and wherein the administration results in a long term disease modification of allergic rhinitis, by the reduction or elimination of one or more allergic rhinitis symptoms for a period of at least 13 weeks following administration of the last dose of ISS.<!-- EPO <DP n="4"> --> Long term disease modification includes the suppression of a Th2 response in the individual. In some cases, the suppression is an inhibition of a Th2 response.</p><heading id="h0006"><u>General Methods</u></heading><p id="p0009" num="0009">The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, nucleic acid chemistry, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, such as, <nplcit id="ncit0003" npl-type="b"><text>Molecular Cloning: A Laboratory Manual, second edition (Sambrook et al., 1989</text></nplcit>) and <nplcit id="ncit0004" npl-type="b"><text>Molecular Cloning: A Laboratory Manual, third edition (Sambrook and Russel, 2001</text></nplcit>), (jointly and individually referred to herein as "Sambrook"); <nplcit id="ncit0005" npl-type="b"><text>Oligonucleotide Synthesis (M. J. Gait, ed., 1984</text></nplcit>); <nplcit id="ncit0006" npl-type="b"><text>Animal Cell Culture (R.I. Freshney, ed., 1987</text></nplcit>); <nplcit id="ncit0007" npl-type="b"><text>Handbook of Experimental Immunology (D.M. Weir &amp; C.C. Blackwell, eds</text></nplcit>.); <nplcit id="ncit0008" npl-type="b"><text>Gene Transfer Vectors for Mammalian Cells (J.M. Miller &amp; M.P. Calos, eds., 1987</text></nplcit>); <nplcit id="ncit0009" npl-type="b"><text>Current Protocols in Molecular Biology (F.M. Ausubel et al., eds., 1987, including supplements through 2001</text></nplcit>); <nplcit id="ncit0010" npl-type="b"><text>PCR: The Polymerase Chain Reaction, (Mullis et al., eds., 1994</text></nplcit>); <nplcit id="ncit0011" npl-type="b"><text>Current Protocols in Immunology (J.E. Coligan et al., eds., 1991</text></nplcit>); <nplcit id="ncit0012" npl-type="b"><text>The Immunoassay Handbook (D. Wild, ed., Stockton Press NY, 1994</text></nplcit>); <nplcit id="ncit0013" npl-type="b"><text>Bioconjugate Techniques (Greg T. Hermanson, ed., Academic Press, 1996</text></nplcit>); <nplcit id="ncit0014" npl-type="b"><text>Methods of Immunological Analysis (R. Masseyeff, W.H. Albert, and N.A. Staines, eds., Weinheim: VCH Verlags gesellschaft mbH, 1993</text></nplcit>), <nplcit id="ncit0015" npl-type="b"><text>Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York</text></nplcit>, <i>and</i> <nplcit id="ncit0016" npl-type="b"><text>Harlow and Lane (1999) Using Antibodies: A Laboratory Manual Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY</text></nplcit> (jointly and individually referred to herein as "Harlow and Lane"), <nplcit id="ncit0017" npl-type="b"><text>Beaucage et al. eds., Current Protocols in Nucleic Acid Chemistry (John Wiley &amp; Sons, Inc., New York, 2000</text></nplcit>); and <nplcit id="ncit0018" npl-type="b"><text>Agrawal, ed., Protocols for Oligonucleotides and Analogs, Synthesis and Properties (Humana Press Inc., New Jersey, 1993</text></nplcit>).</p><heading id="h0007"><u>Definitions</u></heading><p id="p0010" num="0010">As used herein, the term "allergen" means an antigen or antigenic portion of a molecule, usually a protein, which elicits an allergic response upon exposure to a subject. Typically the subject is allergic to the allergen as indicated, for instance, by the wheal and flare<!-- EPO <DP n="5"> --> test or any method known in the art. A molecule is said to be an allergen even if only a small subset of subjects exhibit an allergic immune response (<i>e.g</i>., IgE) upon exposure to the molecule. An allergen may be present in the environment in minute quantities or in larger quantities depending on the season. Examples of allergens are listed in Table 1 <i>infra.</i></p><p id="p0011" num="0011">An "individual" is a vertebrate, such as mouse, and is preferably a mammal, more preferably a human. Mammals include, but are not limited to, humans, primates, farm animals, sport animals, rodents and pets.</p><p id="p0012" num="0012">An "effective amount" of a substance is that amount sufficient to effect beneficial or desired results, including clinical results, and, as such, an "effective amount" depends upon the context in which it is being applied. In the context of administering a composition that modulates an immune response, either with or without a co-administered antigen, an effective amount of an ISS (and antigen, if applicable) is an amount sufficient to achieve such a modulation as compared to the immune response obtained when the antigen is administered alone. An effective amount can confer long term benefits of disease modification, such as suppression and/or inhibition of Th2 immune response. An effective amount can be administered in one or more administrations.</p><p id="p0013" num="0013">As used herein, and as well-understood in the art, "treatment" is an approach for obtaining beneficial or desired results, including clinical results. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation or amelioration of one or more symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, and/or amelioration or palliation of the disease state. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment.</p><p id="p0014" num="0014">As used herein, the term "long term disease modification" refers to the reduction or elimination of one or more allergic rhinitis symptoms for a period of at least 13 weeks following administration of the last dose of ISS. The allergic rhinitis symptoms include, but are not limited to, nasal symptoms (rhinorrhea, congestion, excess nasal secretion/runny nose, sneezing, itching)<!-- EPO <DP n="6"> --> and non-nasal symptoms (itchy/gritty eyes, tearing, watery eyes, red or burning eyes, post-nasal drip, ear or palate itching).</p><heading id="h0008"><u>Biological Effects of ISS</u></heading><p id="p0015" num="0015">It been observed that long term disease modification can be conferred on individuals with allergic rhinitis by using multiple administrations of ISS. The examples provide some illustration of this observation. Example 1 discloses that the direct effects of one type of ISS, the 1018 ISS for example, lasts about one week in a murine model of allergic asthma. Examples 2 and 3 illustrate that the Th2 response can be suppressed in individuals to whom 1018 ISS has been multiply administered for at least 8 weeks. The long term effects of Th2 suppression can last at least 13 weeks. Thus, in one aspect, the invention provides for treating allergic rhinitis long term by administering to an individual an effective amount of ISS for at least 8 weeks. This long term effect of the treatment can last at least 13 weeks. The disclosure contemplates methods for providing the long term benefits for individuals who may have allergic rhinitis by using multiple administration of ISS for at least 8 weeks to confer long term disease modification that persists for at least 13, 15, 17, 19, 21 or 25 weeks.</p><p id="p0016" num="0016">Functionally, ISS enhance the cellular and humoral immune responses in an individual, particularly lymphocyte proliferation and the release of cytokines (including interferon or IFN) by individual monocytes and natural killer (NK) cells. Immunostimulation by synthetic ISS <i>in vivo</i> occurs by contacting individual lymphocytes with, for example ISS, ISS oligonucleotide conjugates and ISS-containing recombinant expression vectors. See, for example, <patcit id="pcit0006" dnum="US6610661B"><text>U.S. Patent No. 6,610,661</text></patcit> and <patcit id="pcit0007" dnum="WO9728259A"><text>WO 97/28259</text></patcit>. Thus, while native microbial ISS stimulate the individual immune system to respond to infection, synthetic analogs of these ISS are useful therapeutically to modulate the individual immune response not only to microbial antigens, but also to allergens and other substances.</p><heading id="h0009"><u>ISS Compositions</u></heading><p id="p0017" num="0017">The invention can be practiced using an ISS containing Cp G motif(s). In one embodiment, the 1018 ISS is used. The structure of 1018 ISS has been published in multiple scientific articles as well as patents. See, for example, <nplcit id="ncit0019" npl-type="s"><text>Hessel et al. (2005) J. Exp. Med., 202(11):1563</text></nplcit>. In general, 1018 ISS is (5'- TGACTGTGAACGTTCGAGATGA - 3').<!-- EPO <DP n="7"> --> See, for example, <patcit id="pcit0008" dnum="US20060058254A"><text>U.S. Publication No. 2006/0058254</text></patcit> or <patcit id="pcit0009" dnum="WO2004058179A"><text>WO 2004/058179</text></patcit>. One or more chimeric immunomodulatory compound ("CIC") can be used. See, for example, <patcit id="pcit0010" dnum="US20040132677A"><text>U.S. Publication No. 2004/0132677</text></patcit>.</p><p id="p0018" num="0018">In accordance with the present invention, the ISS contains at least one palindromic sequence (i.e., palindrome) of at least 8 bases in length containing at least one CG dinucleotide. The ISS also contains at least one TCG trinucleotide sequence at or near the 5'end of the polynucleotide (i.e., 5'-TCG). In some instances, the palindromic sequence and the 5'-TCG are separated by 0, 1 or 2 bases in the ISS. In some instances the palindromic sequence includes all or part of the 5'-TCG.</p><p id="p0019" num="0019">ISSs have been described in the art and their activity may be readily identified using standard assays which indicate various aspects of the immune response, such as cytokine secretion, antibody production, NK cell activation, B cell proliferation, T cell proliferation. See, e.g., <patcit id="pcit0011" dnum="WO9728259A"><text>WO 97/28259</text></patcit>; <patcit id="pcit0012" dnum="WO9816247A"><text>WO 98/16247</text></patcit>; <patcit id="pcit0013" dnum="WO9911275A"><text>WO 99/11275</text></patcit>; <nplcit id="ncit0020" npl-type="s"><text>Krieg et al. (1995) Nature 374:546-549</text></nplcit>; Yamamoto et al. (1992a); Ballas et al. (1996); Klinman et al. (1997); Sato et al. (1996); Pisetsky (1996a); <nplcit id="ncit0021" npl-type="s"><text>Shimada et al. (1986) Jpn. J. Cancer Res. 77:808-816</text></nplcit>; <nplcit id="ncit0022" npl-type="s"><text>Cowdery et al. (1996) J. Immunol. 156:4570-4575</text></nplcit>; Roman et al. (1997); <patcit id="pcit0014" dnum="WO9855495A"><text>Lipford et al. (1997a); WO 98/55495</text></patcit> and <patcit id="pcit0015" dnum="WO0061151A"><text>WO 00/61151</text></patcit>. Accordingly, these and other methods can be used to identify, test and/or confirm immunomodulatory ISSs.</p><p id="p0020" num="0020">The ISS can be of any length greater than 10 bases or base pairs, preferably greater than 15 bases or base pairs, more preferably greater than 20 bases or base pairs in length. It is understood that, with respect to formulae described herein, any and all parameters are independently selected. For example, if x=0-2, y may be independently selected regardless of the values of x (or any other selectable parameter in a formula).</p><p id="p0021" num="0021">In some embodiments, an ISS comprises (a) a palindromic sequence at least 8 bases in length which contains at least two CG dinucleotides, where the CG dinucleotides are separated from each other by 0, 1, 2, 3, 4 or 5 bases, and (b) a (TCG)<sub>y</sub> sequence positioned 0, 1, 2, or 3 bases from the 5' end of the polynucleotide, where y is 1 or 2, and where the 3' end of the (TCG)<sub>y</sub> sequence is separated from the 5' end of the palindromic sequence by 0, 1 or 2 bases. In<!-- EPO <DP n="8"> --> some embodiments, a CG dinucleotide of the (TCG)<sub>y</sub> sequence of (b) may count for one of the at least two CG dinucleotides in the palindromic sequence of (a). In some embodiments, the CG dinucleotides of the palindromic sequence are separated from each other by 1, 3 or 4 bases. In some ISSs of the invention, whether described in this paragraph or elsewhere in the application, the palindromic sequence has a base composition of less than two-thirds G's and C's. In some embodiments, the palindromic sequence has a base composition of greater than one-third A's and T's.</p><p id="p0022" num="0022">In some embodiments, an ISS comprises (a) a palindromic sequence at least 8 bases in length which contains at least two CG dinucleotides, where the CG dinucleotides are separated from each other by 0, 1, 2, 3, 4 or 5 bases, and (b) a (TCG)<sub>y</sub> sequence positioned 0, 1, 2, or 3 bases from the 5' end of the polynucleotide, where y is 1 or 2, where the palindromic sequence includes all or part of the (TCG)<sub>y</sub> sequence, and where a CG dinucleotide of the (TCG)<sub>y</sub> sequence of (b) may count for one of the CG dinucleotides of the palindromic sequence of (a). Preferably, in some embodiments, the CG dinucleotides of the palindromic sequence are separated from each other by 1, 3 or 4 bases.</p><p id="p0023" num="0023">Accordingly, in some embodiments, an ISS may comprise a sequence of the formula: 5'-N<sub>x</sub>(TCG(N<sub>q</sub>))<sub>y</sub>N<sub>w</sub>(X<sub>1</sub>CGX<sub>1</sub>'(CG)<sub>p</sub>)<sub>z</sub> wherein N are nucleosides with x = 0-3, y = 1-4, w = -1, 0, 1 or 2, p= 0 or 1, q = 0, 1 or 2, and z = 1-20, wherein X<sub>1</sub> and X<sub>1</sub>' are self-complimentary and wherein the 5' T of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is 0-3 bases from the 5' end of the polynucleotide. The ISS further comprises a palindromic sequence 8 bases in length or greater wherein the palindromic sequence comprises at least one of the (X<sub>1</sub>CGX<sub>1</sub>'(CG)<sub>p</sub>) sequences. In an ISS with w = -1, the 3' base of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is the 5' X<sub>1</sub> of the first (X<sub>1</sub>CGX<sub>1</sub>'(CG)<sub>p</sub>) sequence. In some embodiments, the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is separated from the palindromic sequence by 0, 1 or 2 bases. In other embodiments, the palindromic sequence includes all or part of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence. In some embodiments, when p=0, X<sub>1</sub> is either A or T.</p><p id="p0024" num="0024">In some embodiments, an ISS may comprise a sequence of the formula: 5'-N<sub>x</sub>(TCG(N<sub>q</sub>))<sub>y</sub>N<sub>w</sub>(X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>CGX<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>)<sub>z</sub> wherein N are nucleosides with x = 0-3, y = 1-4, w = -3, -2, -1, 0, 1 or 2, p= 0 or 1, q = 0, 1 or 2, and z = 1-20, wherein X<sub>1</sub> and X<sub>1</sub>', X<sub>2</sub> and X<sub>2</sub>', and X<sub>3</sub> and X<sub>3</sub>' are self-complimentary and wherein the 5' T of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is 0-3 bases from the 5' end of the polynucleotide. The ISS further comprises a palindromic sequence<!-- EPO <DP n="9"> --> 8 bases in length or greater wherein the palindromic sequence comprises the first (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>CGX<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>') of the at least one (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>CGX<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In an ISS with w = -1, the 3' base of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is the 5' X<sub>1</sub> of the first (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>CGX<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In an ISS with w = -2, the penultimate (i.e., second to last) and the ultimate (i.e., last) 3' bases of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence are the 5' X<sub>1</sub> and X<sub>2</sub>, respectively, of the first (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>CGX<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In an ISS with w = -3, the antepenultimate (i.e., third to last), the penultimate (i.e., second to last) and the ultimate (i.e., last) 3' bases of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence are the 5' X<sub>1</sub>, X<sub>2</sub>, and X<sub>3</sub>, respectively, of the first (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>CGX<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>'(CG)p) sequence. In some embodiments, the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is separated from the palindromic sequence by 0, 1 or 2 bases. In other embodiments, the palindromic sequence includes all or part of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence. In some embodiments, when p=1, X<sub>1</sub>, X<sub>2</sub>, and X<sub>3</sub> are each either A or T. In some embodiments, when p=0, at least two of X<sub>1</sub>, X<sub>2</sub>, and X<sub>3</sub> are either A or T.</p><p id="p0025" num="0025">In some embodiments, an ISS may comprise a sequence of the formula: 5'-N<sub>x</sub>(TCG(N<sub>q</sub>))<sub>y</sub>N<sub>w</sub>(X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>CGX<sub>4</sub>'X<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>)<sub>z</sub> wherein N are nucleosides with x = 0-3, y = 1-4, w = -3, -2, -1, 0, 1 or 2, p= 0 or 1, q = 0, 1 or 2, and z = 1-20, wherein X<sub>1</sub> and X<sub>1</sub>', X<sub>2</sub> and X<sub>2</sub>', X<sub>3</sub> and X<sub>3</sub>', and X<sub>4</sub> and X<sub>4</sub>' are self-complimentary and wherein the 5' T of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is 0-3 bases from the 5' end of the polynucleotide. The ISS further comprises a palindromic sequence 10 bases in length or greater wherein the palindromic sequence comprises the first (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>CGX<sub>4</sub>'X<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>') of the at least one (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>CGX<sub>4</sub>'X<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In an ISS with w = -1, the 3' base of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is the 5' X<sub>1</sub> of the first (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>CGX<sub>4</sub>'X<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In an ISS with w = -2, the penultimate (i.e., second to last) and the ultimate (i.e., last) 3' bases of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence are the 5' X<sub>1</sub> and X<sub>2</sub>, respectively, of the first (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>CGX<sub>4</sub>'X<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In an ISS with w =-3, the antepenultimate (i.e., third to last), the penultimate (i.e., second to last) and the ultimate (i.e., last) 3' bases of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence are the 5' X<sub>1</sub>, X<sub>2</sub>, and X<sub>3</sub>, respectively, of the first (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>CGX<sub>4</sub>'X<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In some embodiments, the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is separated from the palindromic sequence by 0, 1 or 2 bases. In other embodiments, the palindromic sequence includes all or part of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence. In some embodiments, when p=1, at least three of X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, and X<sub>4</sub> are either A or T. In some embodiments, when p=0, at least two of X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, and X<sub>4</sub> are either A or T.<!-- EPO <DP n="10"> --></p><p id="p0026" num="0026">In some embodiments, an ISS may comprise a sequence of the formula: 5'-N<sub>x</sub>(TCG(N<sub>q</sub>))<sub>y</sub>N<sub>w</sub>(X<sub>1</sub>CGCGX<sub>1</sub>'(CG)<sub>p</sub>)<sub>z</sub> wherein N are nucleosides with x = 0-3, y = 1-4, w = -1, 0, 1 or 2, p = 0 or 1, q = 0, 1 or 2, and z = 1-20, wherein X<sub>1</sub> and X<sub>1</sub>' are self-complimentary and wherein the 5' T of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is 0-3 bases from the 5' end of the polynucleotide. The ISS further comprises a palindromic sequence 8 bases in length or greater wherein the palindromic sequence comprises the first (X<sub>1</sub>CGCGX<sub>1</sub>') of the at least one (X<sub>1</sub>CGCGX<sub>1</sub>'(CG)<sub>p</sub>) sequence. In an ISS with w = -1, the 3' base of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is the 5' X<sub>1</sub> of the first (X<sub>1</sub>CGCGX<sub>1</sub>'(CG)<sub>p</sub>) sequence. In some embodiments, the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is separated from the palindromic sequence by 0, 1 or 2 bases. In other embodiments, the palindromic sequence includes all or part of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence.</p><p id="p0027" num="0027">In some embodiments, an ISS may comprise a sequence of the formula: 5'-N<sub>x</sub>(TCG(N<sub>q</sub>))<sub>y</sub>N<sub>w</sub>(CGX<sub>1</sub>X<sub>1</sub>'CG(CG)<sub>p</sub>)<sub>z</sub> wherein N are nucleosides with x = 0-3, y = 1-4, w = -2, 0, 1 or 2, p= 0 or 1, q = 0, 1 or 2, and z = 1-20, wherein X<sub>1</sub> and X<sub>1</sub>' are self-complimentary and wherein the 5' T of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is 0-3 bases from the 5' end of the polynucleotide. The ISS further comprises a palindromic sequence 8 bases in length or greater wherein the palindromic sequence comprises the first (CGX<sub>1</sub>X<sub>1</sub>'CG) of the at least one (CGX<sub>1</sub>X<sub>1</sub>'CG(CG)<sub>p</sub>) sequence. In an ISS with w = -2, the penultimate (i.e., second to last) and the ultimate (i.e., last) 3' bases of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence are CG and are the 5' CG of the first (CGX<sub>1</sub>X<sub>1</sub>'CG(CG)<sub>p</sub>) sequence. In some embodiments, the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is separated from the palindromic sequence by 0, 1 or 2 bases. In other embodiments, the palindromic sequence includes all or part of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence.</p><p id="p0028" num="0028">In some embodiments, an ISS may comprise a sequence of the formula: 5'-N<sub>x</sub>(TCG(N<sub>q</sub>))<sub>y</sub>N<sub>w</sub>(X<sub>1</sub>X<sub>2</sub>CGX<sub>3</sub>X<sub>3</sub>'CGX<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>)<sub>z</sub> wherein N are nucleosides with x = 0-3, y = 1-4, w = -2, -1, 0, 1 or 2, p= 0 or 1, q = 0, 1 or 2, and z = 1-20, wherein X<sub>1</sub> and X<sub>1</sub>', X<sub>2</sub> and X<sub>2</sub>', and X<sub>3</sub> and X<sub>3</sub>' are self-complimentary and wherein the 5' T of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is 0-3 bases from the 5' end of the polynucleotide. The ISS further comprises a palindromic sequence 10 bases in length or greater wherein the palindromic sequence comprises the first (X<sub>1</sub>X<sub>2</sub>CGX<sub>3</sub>X<sub>3</sub>'CGX<sub>2</sub>'X<sub>1</sub>') of the at least one (X<sub>1</sub>X<sub>2</sub>CGX<sub>3</sub>X<sub>3</sub>'CGX<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In an ISS with w = -1, the 3' base of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is the 5' X<sub>1</sub> of the first (X<sub>1</sub>X<sub>2</sub>CGX<sub>3</sub>X<sub>3</sub>'CGX<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In an ISS with w = -2, the penultimate (i.e., second<!-- EPO <DP n="11"> --> to last) and the ultimate (i.e., last) 3' bases of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence are the 5' X<sub>1</sub> and X<sub>2</sub>, respectively, of the first (X<sub>1</sub>X<sub>2</sub>CGX<sub>3</sub>X<sub>3</sub>CGX<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In some embodiments, the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is separated from the palindromic sequence by 0, 1 or 2 bases. In other embodiments, the palindromic sequence includes all or part of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence. In some embodiments, when p=1, X<sub>1</sub>, X<sub>2</sub>, and X<sub>3</sub> are each either A or T. In some embodiments, when p=0, at least two of X<sub>1</sub>, X<sub>2</sub>, and X<sub>3</sub> are either A or T.</p><p id="p0029" num="0029">In some embodiments, an ISS may comprise a sequence of the formula: 5'-N<sub>x</sub>(TCG(N<sub>q</sub>))<sub>y</sub>N<sub>w</sub>(X<sub>1</sub>X<sub>2</sub>CGX<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>)<sub>z</sub> wherein N are nucleosides with x = 0-3, y = 1-4, w =-2, -1, 0, 1 or 2, p= 0 or 1, q = 0, 1 or 2, and z = 1-20, wherein X<sub>1</sub> and X<sub>1</sub>', X<sub>2</sub> and X<sub>2</sub>' are self-complimentary, and wherein the 5' T of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is 0-3 bases from the 5' end of the polynucleotide. The ISS further comprises a palindromic sequence 8 bases in length or greater wherein the palindromic sequence comprises the first (X<sub>1</sub>X<sub>2</sub>CGX<sub>2</sub>'X<sub>1</sub>') of the at least one (X<sub>1</sub>X<sub>2</sub>CGX<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>)<sub>z</sub> sequence. In an ISS with w = -1, the 3' base of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is the 5' X<sub>1</sub> of the first (X<sub>1</sub>X<sub>2</sub>CGX<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In an ISS with w = -2, the penultimate (i.e., second to last) and the ultimate (i.e., last) 3' bases of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence are the 5' X<sub>1</sub> and X<sub>2</sub>, respectively, of the first (X<sub>1</sub>X<sub>2</sub>CGX<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In some embodiments, the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is separated from the palindromic sequence by 0, 1 or 2 bases. In other embodiments, the palindromic sequence includes all or part of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence. In some embodiments, X<sub>1</sub> and X<sub>2</sub> are each either A or T.</p><p id="p0030" num="0030">In some embodiments, an ISS may comprise a sequence of the formula: 5'-N<sub>x</sub>(TCG(N<sub>q</sub>))<sub>y</sub>N<sub>w</sub>(X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>X<sub>5</sub>CGX<sub>5</sub>'X<sub>4</sub>'X<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>)<sub>z</sub> wherein N are nucleosides with x = 0-3, y = 1-4, w = -3, -2, -1, 0, 1 or 2, p= 0 or 1, q = 0, 1 or 2, and z = 1-20, wherein X<sub>1</sub> and X<sub>1</sub>', X<sub>2</sub> and X<sub>2</sub>', X<sub>3</sub> and X<sub>3</sub>', X<sub>4</sub> and X<sub>4</sub>', and X<sub>5</sub> and X<sub>5</sub>' are self-complimentary, and wherein the 5' T of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is 0-3 bases from the 5' end of the polynucleotide. The ISS further comprises a palindromic sequence 12 bases in length or greater wherein the palindromic sequence comprises the first (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>X<sub>5</sub>CGX<sub>5</sub>'X<sub>4</sub>'X<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>') of the at least one ((X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>X<sub>5</sub>CGX<sub>5</sub>'X<sub>4</sub>'X<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In an ISS with w = -1, the 3' base of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is the 5' X<sub>1</sub> of the first (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>X<sub>5</sub>CGX<sub>5</sub>'X<sub>4</sub>'X<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In an ISS with w = -2, the penultimate (i.e., second to last) and the ultimate (i.e., last) 3' bases of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence are the 5' X<sub>1</sub> and X<sub>2</sub>, respectively, of the first<!-- EPO <DP n="12"> --> (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>x<sub>4</sub>X<sub>5</sub>CGX<sub>5</sub>'X<sub>4</sub>'X<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In an ISS with w = -3, the antepenultimate (i.e., third to last), the penultimate (i.e., second to last) and the ultimate (i.e., last) 3' bases of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence are the 5' X<sub>1</sub>, X<sub>2</sub>, and X<sub>3</sub>, respectively, of the first (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>X<sub>5</sub>CGX<sub>5</sub>'X<sub>4</sub>'X<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In some embodiments, the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is separated from the palindromic sequence by 0, 1 or 2 bases. In other embodiments, the palindromic sequence includes all or part of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence. In some embodiments, at least three of X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, X<sub>4</sub>, and X<sub>5</sub> are either A or T.</p><p id="p0031" num="0031">In some embodiments, an ISS may comprise a sequence of the formula: 5'-N<sub>x</sub>(TCG(N<sub>q</sub>))yN<sub>w</sub>(X<sub>1</sub>X<sub>2</sub>CGCGX<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>)<sub>z</sub> wherein N are nucleosides with x = 0-3, y = 1-4, w = -2, -1, 0, 1 or 2, p= 0 or 1, q = 0, 1 or 2, and z = 1-20, wherein X<sub>1</sub> and X<sub>1</sub>', and X<sub>2</sub> and X<sub>2</sub>' are self-complimentary, and wherein the 5' T of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is 0-3 bases from the 5' end of the polynucleotide. The ISS further comprises a palindromic sequence 8 bases in length or greater wherein the palindromic sequence comprises the first (X<sub>1</sub>X<sub>2</sub>CGCGX<sub>2</sub>'X<sub>1</sub>') of the at least one (X<sub>1</sub>X<sub>2</sub>CGCGX<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In an ISS with w = -1, the 3' base of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is the 5' X<sub>1</sub> of the first (X<sub>1</sub>X<sub>2</sub>CGCGX<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In an ISS with w = -2, the penultimate (i.e., second to last) and the ultimate (i.e., last) 3' bases of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence are the 5' X<sub>1</sub> and X<sub>2</sub>, respectively, of the first (X<sub>1</sub>X<sub>2</sub>CGCGX<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In some embodiments, the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is separated from the palindromic sequence by 0, 1 or 2 bases. In other embodiments, the palindromic sequence includes all or part of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence. In some embodiments, X<sub>1</sub> and X<sub>2</sub> are each either A or T.</p><p id="p0032" num="0032">In some embodiments, an ISS may comprise a sequence of the formula: 5'-N<sub>x</sub>(TCG(N<sub>q</sub>))<sub>y</sub>N<sub>w</sub>(X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>CGCGX<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>)<sub>z</sub> wherein N are nucleosides with x = 0-3, y = 1-4, w = -3, -2, -1, 0, 1 or 2, p= 0 or 1, q = 0, 1 or 2, and z = 1-20, wherein X<sub>1</sub> and X<sub>1</sub>', X<sub>2</sub> and X<sub>2</sub>' and X<sub>3</sub> and X<sub>3</sub>' are self-complimentary, and wherein the 5' T of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is 0-3 bases from the 5' end of the polynucleotide. The ISS further comprises a palindromic sequence 10 bases in length or greater wherein the palindromic sequence comprises the first (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>CGCGX<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>') of the at least one (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>CGCGX<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In an ISS with w = -1, the 3' base of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is the 5' X<sub>1</sub> of the first (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>CGCGX<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In an ISS with w = -2, the penultimate (i.e., second to last) and the ultimate (i.e., last) 3' bases of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence are the 5' X<sub>1</sub> and X<sub>2</sub>,<!-- EPO <DP n="13"> --> respectively, of the first (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>CGCGX<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In an ISS with w = -3, the antepenultimate (i.e., third to last), the penultimate (i.e., second to last) and the ultimate (i.e., last) 3' bases of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence are the 5' X<sub>1</sub>, X<sub>2</sub>, and X<sub>3</sub>, respectively, of the first (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>CGCGX<sub>3</sub>'X<sub>2</sub>'X<sub>1</sub>'(CG)<sub>p</sub>) sequence. In some embodiments, the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is separated from the palindromic sequence by 0, 1 or 2 bases. In other embodiments, the palindromic sequence includes all or part of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence. In some embodiments, when p=1, X<sub>1</sub>, X<sub>2</sub>, and X<sub>3</sub> are each either A or T. In some embodiments, when p=0, at least two of X<sub>1</sub>, X<sub>2</sub>, and X<sub>3</sub> are either A or T.</p><p id="p0033" num="0033">In some embodiments, an ISS may comprise a sequence of the formula: 5'-N<sub>x</sub>(TCG(N<sub>q</sub>))<sub>y</sub>N<sub>w</sub>(CGX<sub>1</sub>X<sub>2</sub>X<sub>2</sub>'X<sub>1</sub>'CG(CG)<sub>p</sub>)<sub>z</sub> wherein N are nucleosides with x = 0-3, y = 1-4, w = -2, 0, 1 or 2, p= 0 or 1, q = 0, 1 or 2, and z = 1-20, wherein X<sub>1</sub> and X<sub>1</sub>', and X<sub>2</sub> and X<sub>2</sub>' are self-complimentary, and wherein the 5' T of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is 0-3 bases from the 5' end of the polynucleotide. The ISS further comprises a palindromic sequence 8 bases in length or greater wherein the palindromic sequence comprises the first (CGX<sub>1</sub>X<sub>2</sub>X<sub>2</sub>'X<sub>1</sub>'CG) of the at least one (CGX<sub>1</sub>X<sub>2</sub>X<sub>2</sub>'X<sub>1</sub>'CG(CG)<sub>p</sub>) sequence. In an ISS with w = -2, the penultimate (i.e., second to last) and the ultimate (i.e., last) 3' bases of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence are CG and are the 5' CG of the first (CGX<sub>1</sub>X<sub>2</sub>X<sub>2</sub>'X<sub>1</sub>'CG(CG)<sub>p</sub>) sequence. In some embodiments, the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is separated from the palindromic sequence by 0, 1 or 2 bases. In other embodiments, the palindromic sequence includes all or part of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence. In some embodiments, X<sub>1</sub> and X<sub>2</sub> are each either A or T.</p><p id="p0034" num="0034">For ISSs comprising any of the motifs described herein where y = 2 or more, the (Nq) in each of the y repetitions of the (TCG(Nq)) is independently selected. For example, in an ISS with y = 2, the first TCG(N<sub>q</sub>) may have N = A and q = 1 and the second TCG(N<sub>q</sub>) may have q = 0 in which case this portion of the ISS would be ...TCGATCG.... In some embodiments of ISSs comprising any of the motifs described herein in some embodiments, x is preferably 0 or 1. In some embodiments of ISSs comprising any of the motifs described herein, y is preferably 1 or 2. In some embodiments of ISSs comprising any of the motifs described herein, w is preferably 0. In some embodiments of ISSs comprising any of the motifs described herein, z is preferably 1, 2, 3, 4, 5, 6, 7 or 8.<!-- EPO <DP n="14"> --></p><p id="p0035" num="0035">As noted above, the ISSs contain at least one the palindromic sequence at least 8 bases in length. In some embodiments, an ISS contains at least one palindromic sequence of at least the following lengths (in bases): 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30. In some embodiments, the palindromic sequence is repeated at least once in an ISS. In some embodiments, the palindromic sequence also includes bases 5' of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence, if any.</p><p id="p0036" num="0036">Non-limiting examples of specific ISSs that can be used in accordance with the teachings above can be found in <patcit id="pcit0016" dnum="US20060058254A"><text>U.S. Publication No. 2006/0058254</text></patcit> and also in <patcit id="pcit0017" dnum="US20040132677A"><text>U.S. Publication No. 2004/0132677</text></patcit>.</p><heading id="h0010"><u>Modifications to ISS</u></heading><p id="p0037" num="0037">An ISS may contain modifications. Modifications of ISS include any known in the art, but are not limited to, modifications of the 3'OH or 5'OH group, modifications of the nucleotide base, modifications of the sugar component, and modifications of the phosphate group. Modified bases may be included in the palindromic sequence of an ISS as long as the modified base(s) maintains the same specificity for its natural complement through Watson-Crick base pairing (e.g., the palindromic portion of the ISS is still self-complementary).</p><p id="p0038" num="0038">An ISS may contain naturally-occurring or modified, non-naturally occurring bases, and may contain modified sugar, phosphate, and/or termini. For example, in addition to phosphodiester linkages, phosphate modifications include, but are not limited to, methyl phosphonate, phosphorothioate, phosphoramidate (bridging or non-bridging), phosphotriester and phosphorodithioate and may be used in any combination. Other non-phosphate linkages may also be used. In some embodiments, polynucleotides of the present invention comprise only phosphorothioate backbones. In some embodiments, polynucleotides of the present invention comprise only phosphodiester backbones. In some embodiments, an ISS may comprise a combination of phosphate linkages in the phosphate backbone such as a combination of phosphodiester and phosphorothioate linkages.</p><p id="p0039" num="0039">Sugar modifications known in the field, such as 2'-alkoxy-RNA analogs, 2'-amino-RNA analogs, 2'-fluoro-DNA, and 2'-alkoxy- or amino-RNA/DNA chimeras and others described herein, may also be made and combined with any phosphate modification. Examples<!-- EPO <DP n="15"> --> of base modifications include, but are not limited to, addition of an electron-withdrawing moiety to C-5 and/or C-6 of a cytosine of the ISS (e.g., 5-bromocytosine, 5-chlorocytosine, 5-fluorocytosine, 5-iodocytosine) and C-5 and/or C-6 of a uracil of the ISS (e.g., 5-bromouracil, 5-chlorouracil, 5-fluorouracil, 5-iodouracil). See, for example, <patcit id="pcit0018" dnum="WO9962923A"><text>WO 99/62923</text></patcit>. The use of a base modification in a palindromic sequence of an ISS should not interfere with the self-complimentary ability of the bases involved for Watson-Crick base pairing. However, outside of a palindromic sequence, modified bases may be used without this restriction.</p><p id="p0040" num="0040">In addition, backbone phosphate group modifications (e.g., methylphosphonate, phosphorothioate, phosphoroamidate and phosphorodithioate internucleotide linkages) can confer immunomodulatory activity on the ISS and enhance their stability <i>in vivo,</i> making them particularly useful in therapeutic applications. A particularly useful phosphate group modification is the conversion to the phosphorothioate or phosphorodithioate forms of the ISS oligonucleotides. In addition to their potentially immunomodulatory properties, phosphorothioates and phosphorodithioates are more resistant to degradation in vivo than their unmodified oligonucleotide counterparts, making the ISS of the invention more available to the individual.</p><heading id="h0011"><u>Synthesis of and Screening for ISS</u></heading><p id="p0041" num="0041">The ISS can be synthesized using techniques and nucleic acid synthesis equipment which are well known in the art including, but not limited to, enzymatic methods, chemical methods, and the degradation of larger oligonucleotide sequences. See, for example, Ausubel et al. (1987) and Sambrook et al. (1989). When assembled enzymatically, the individual units can be ligated, for example, with a ligase such as T4 DNA or RNA ligase. See, for example, <patcit id="pcit0019" dnum="US5124246A"><text>U.S. Patent No. 5,124,246</text></patcit>. Oligonucleotide degradation can be accomplished through the exposure of an oligonucleotide to a nuclease, as exemplified in <patcit id="pcit0020" dnum="US4650675A"><text>U.S. Patent No. 4,650,675</text></patcit>.</p><p id="p0042" num="0042">The ISS can also be isolated using conventional polynucleotide isolation procedures. Such procedures include, but are not limited to, hybridization of probes to genomic or cDNA libraries to detect shared nucleotide sequences, antibody screening of expression libraries to detect shared structural features and synthesis of particular native sequences by the polymerase chain reaction.<!-- EPO <DP n="16"> --></p><p id="p0043" num="0043">Circular ISS can be isolated, synthesized through recombinant methods, or chemically synthesized. Where the circular ISS is obtained through isolation or through recombinant methods, the ISS will preferably be a plasmid. The chemical synthesis of smaller circular oligonucleotides can be performed using any method described in the literature. See, for instance, <nplcit id="ncit0023" npl-type="s"><text>Gao et al. (1995) Nucleic Acids Res. 23:2025-2029</text></nplcit>; and <nplcit id="ncit0024" npl-type="s"><text>Wang et al. (1994) Nucleic Acids Res. 22:2326-2333</text></nplcit>.</p><p id="p0044" num="0044">Duplex (i.e., double stranded) and hairpin forms of most ISSs are in dynamic equilibrium, with the hairpin form generally favored at low polynucleotide concentration and higher temperatures. Covalent interstrand or intrastrand cross-links increases duplex or hairpin stability, respectively, towards thermal-, ionic-, pH-, and concentration-induced conformational changes. Chemical cross-links can be used to lock the polynucleotide into either the duplex or the hairpin form for physicochemical and biological characterization. Cross-linked ISSs that are conformationally homogeneous and are "locked" in their most active form (either duplex or hairpin form) could potentially be more active than their uncross-linked counterparts. Accordingly, some ISSs of the invention contain covalent interstrand and/or intrastrand cross-links.</p><p id="p0045" num="0045">A variety of ways to chemically cross-link duplex DNA are known in the art. Any cross-linking method may be used as long as the cross-linked polynucleotide product possesses the desired immunomodulatory activity.</p><p id="p0046" num="0046">One method, for example, results in a disulfide bridge between two opposing thymidines at the terminus of the duplex or hairpin. For this cross-linking method, the oligonucleotide(s) of interest is synthesized with a 5'-DMT-<i>N</i>3-(tBu-SS-ethyl)thymidine-3'-phosphoramidite ("T*"). To form the disulfide bridge, the mixed disulfide bonds are reduced, oligonucleotide purified, the strands hybridized and the compound air-oxidized to form the intrastrand cross-link in the case of a hairpin form or the interstrand cross-link in the case of a duplex form. Alternatively, the oligonucleotides may be hybridized first and then reduced, purified and air-oxidized. Such methods and others are described, for example, in <nplcit id="ncit0025" npl-type="s"><text>Glick et al. (1991) J. Org. Chem. 56:6746-6747</text></nplcit>, <nplcit id="ncit0026" npl-type="s"><text>Glick et al. (1992) J. Am. Chem. Soc. 114:5447-5448</text></nplcit>, <nplcit id="ncit0027" npl-type="s"><text>Goodwin et al. (1994) Tetrahedron Letters 35:1647-1650</text></nplcit>, <nplcit id="ncit0028" npl-type="s"><text>Wang et al. (1995) J. Am. Chem. Soc.<!-- EPO <DP n="17"> --> 117:2981-2991</text></nplcit>, <nplcit id="ncit0029" npl-type="s"><text>Osborne et al. (1996) Bioorganic &amp; Medicinal Chemistry Letters 6:2339-2342</text></nplcit> and <nplcit id="ncit0030" npl-type="s"><text>Osborne et al. (1996) J. Am. Chem. Soc. 118:11993-12003</text></nplcit>.</p><p id="p0047" num="0047">Another cross-linking method forms a disulfide bridge between offset residues in the duplex or hairpin structure. For this cross-linking method, the oligonucleotide(s) of interest is synthesized with convertible nucleosides (commercially available, for example, from Glen Research). This method utilizes, for example, an A-A disulfide or a C-A disulfide bridge and linkages through other bases are also possible. To form the disulfide-modified polynucleotide, the polynucleotide containing the convertible nucleoside is reacted with cystamine (or other disulfide-containing amine). To form the disulfide bridge, the mixed disulfide bonds are reduced, oligonucleotide purified, the strands hybridized and the compound air-oxidized to form the intrastrand cross-link in the case of a hairpin form or the interstrand cross-link in the case of a duplex form. Alternatively, the oligonucleotides may be hybridized first and then reduced, purified and air-oxidized. Such methods and others are described, for example, in <nplcit id="ncit0031" npl-type="s"><text>Glick et al. (1991) J. Org. Chem. 56:6746-6747</text></nplcit>, <nplcit id="ncit0032" npl-type="s"><text>Glick et al. (1992) J. Am. Chem. Soc. 114:5447-5448</text></nplcit>, <nplcit id="ncit0033" npl-type="s"><text>Goodwin et al. (1994) Tetrahedron Letters 35:1647-1650</text></nplcit>, <nplcit id="ncit0034" npl-type="s"><text>Wang et al. (1995) J. Am. Chem. Soc. 117:2981-2991</text></nplcit>, <nplcit id="ncit0035" npl-type="s"><text>Osborne et al. (1996) Bioorganic &amp; Medicinal Chemistry Letters 6:2339-2342</text></nplcit> and <nplcit id="ncit0036" npl-type="s"><text>Osborne et al. (1996) J. Am. Chem. Soc. 118:11993-12003</text></nplcit>.</p><p id="p0048" num="0048">Another cross-linking method forms a disulfide bridge between offset residues in the duplex or hairpin structure. For this cross-linking method, the oligonucleotide(s) of interest is synthesized with convertible nucleosides (commercially available, for example, from Glen Research). This method utilizes, for example, an A-A disulfide or a C-A disulfide bridge and linkages through other bases are also possible. To form the disulfide-modified polynucleotide, the polynucleotide containing the convertible nucleoside is reacted with cystamine (or other disulfide-containing amine). To form the disulfide bridge, the mixed disulfide bonds are reduced, oligonucleotide purified, the strands hybridized and the compound air-oxidized to form the intrastrand cross-link in the case of a hairpin form or the interstrand cross-link in the case of a duplex form. Alternatively, the oligonucleotides may be hybridized first and then reduced, purified and air-oxidized. Such methods are described, for example, in <nplcit id="ncit0037" npl-type="s"><text>Ferentz et al. (1991) J. Am. Chem. Soc. 113:4000-4002</text></nplcit> and <nplcit id="ncit0038" npl-type="s"><text>Ferentz et al. (1993) J. Am. Chem. Soc. 115:9006-9014</text></nplcit>.<!-- EPO <DP n="18"> --></p><p id="p0049" num="0049">The techniques for making polynucleotides and modified polynucleotides are known in the art. Naturally occurring DNA or RNA, containing phosphodiester linkages, is generally synthesized by sequentially coupling the appropriate nucleoside phosphoramidite to the 5'-hydroxy group of the growing oligonucleotide attached to a solid support at the 3'-end, followed by oxidation of the intermediate phosphite triester to a phosphate triester. Once the desired polynucleotide sequence has been synthesized, the polynucleotide is removed from the support, the phosphate triester groups are deprotected to phosphate diesters and the nucleoside bases are deprotected using aqueous ammonia or other bases. See, for example, <nplcit id="ncit0039" npl-type="b"><text>Beaucage (1993) "Oligodeoxyribonucleotide Synthesis" in Protocols for Oligonucleotides and Analogs, Synthesis and Properties (Agrawal, ed.) Humana Press, Totowa, NJ</text></nplcit>; <nplcit id="ncit0040" npl-type="s"><text>Warner et al. (1984) DNA 3:401 </text></nplcit>and <patcit id="pcit0021" dnum="US4458066A"><text>U.S. Patent No. 4,458,066</text></patcit>.</p><p id="p0050" num="0050">The ISS can also contain phosphate-modified polynucleotides, some of which are known to stabilize the polynucleotide. Accordingly, some embodiments includes stabilized ISSs. Synthesis of polynucleotides containing modified phosphate linkages or non-phosphate linkages is also known in the art. For a review, see <nplcit id="ncit0041" npl-type="b"><text>Matteucci (1997) "Oligonucleotide Analogs: an Overview" in Oligonucleotides as Therapeutic Agents, (D.J. Chadwick and G. Cardew, ed.) John Wiley and Sons, New York, NY</text></nplcit>. The phosphorous derivative (or modified phosphate group) which can be attached to the sugar or sugar analog moiety in the polynucleotides of the present invention can be a monophosphate, diphosphate, triphosphate, alkylphosphonate, phosphorothioate, phosphorodithioate, phosphoramidate or the like. The preparation of the above-noted phosphate analogs, and their incorporation into nucleotides, modified nucleotides and oligonucleotides, per se, is also known and need not be described here in detail. <nplcit id="ncit0042" npl-type="s"><text>Peyrottes et al. (1996) Nucleic Acids Res. 24:1841-1848</text></nplcit>; <nplcit id="ncit0043" npl-type="s"><text>Chaturvedi et al. (1996) Nucleic Acids Res. 24:2318-2323</text></nplcit>; and <nplcit id="ncit0044" npl-type="s"><text>Schultz et al. (1996) Nucleic Acids Res. 24:2966-2973</text></nplcit>. For example, synthesis of phosphorothioate oligonucleotides is similar to that described above for naturally occurring oligonucleotides except that the oxidation step is replaced by a sulfurization step (<nplcit id="ncit0045" npl-type="b"><text>Zon (1993) "Oligonucleoside Phosphorothioates" in Protocols for Oligonucleotides and Analogs, Synthesis and Properties (Agrawal, ed.) Humana Press, pp. 165-190</text></nplcit>). Similarly the synthesis of other phosphate analogs, such as phosphotriester (<nplcit id="ncit0046" npl-type="s"><text>Miller et al. (1971) JACS 93:6657-6665</text></nplcit>), non-bridging phosphoramidates (<nplcit id="ncit0047" npl-type="s"><text>Jager et al. (1988) Biochem. 27:7247-7246</text></nplcit>), N3' to P5' phosphoramidiates (<nplcit id="ncit0048" npl-type="s"><text>Nelson et al. (1997) JOC 62:7278-7287</text></nplcit>) and phosphorodithioates (<patcit id="pcit0022" dnum="US5453496A"><text>U.S.<!-- EPO <DP n="19"> --> Patent No. 5,453,496</text></patcit>) has also been described. Other non-phosphorous based modified oligonucleotides can also be used (<nplcit id="ncit0049" npl-type="s"><text>Stirchak et al. (1989) Nucleic Acids Res. 17:6129-6141</text></nplcit>). Polynucleotides with phosphorothioate backbones can be more immunogenic than those with phosphodiester backbones and appear to be more resistant to degradation after injection into the host. <nplcit id="ncit0050" npl-type="s"><text>Braun et al. (1988) J. Immunol. 141:2084-2089</text></nplcit>; and <nplcit id="ncit0051" npl-type="s"><text>Latimer et al. (1995) Mol. Immuuol. 32:1057-1064</text></nplcit>.</p><p id="p0051" num="0051">ISSs used in the invention can comprise one or more ribonucleotides (containing ribose as the only or principal sugar component), deoxyribonucleotides (containing deoxyribose as the principal sugar component), or, as is known in the art, modified sugars or sugar analogs can be incorporated in the ISS. Thus, in addition to ribose and deoxyribose, the sugar moiety can be pentose, deoxypentose, hexose, deoxyhexose, glucose, arabinose, xylose, lyxose, and a sugar "analog" cyclopentyl group. The sugar can be in pyranosyl or in a furanosyl form. In the ISS, the sugar moiety is preferably the furanoside of ribose, deoxyribose, arabinose or 2'-0-alkylribose, and the sugar can be attached to the respective heterocyclic bases either in <b>α</b> or <b>β</b> anomeric configuration. Sugar modifications include, but are not limited to, 2'-alkoxy-RNA analogs, 2'-amino-RNA analogs, 2'-fluoro-DNA, and 2'-alkoxy- or amino-RNA/DNA chimeras. For example, a sugar modification in the ISS includes, but is not limited to, 2'-O-methyl-uridine and 2'-O-methyl-cytidine. The preparation of these sugars or sugar analogs and the respective "nucleosides" wherein such sugars or analogs are attached to a heterocyclic base (nucleic acid base) per se is known, and need not be described here, except to the extent such preparation can pertain to any specific example. Sugar modifications may also be made and combined with any phosphate modification in the preparation of an ISS.</p><p id="p0052" num="0052">The heterocyclic bases, or nucleic acid bases, which are incorporated in the ISS can be the naturally-occurring principal purine and pyrimidine bases, (namely uracil, thymine, cytosine, adenine and guanine, as mentioned above), as well as naturally-occurring and synthetic modifications of said principal bases. Thus, an ISS may include 2'-deoxyuridine and/or 2-amino-2'-deoxyadenosine.</p><p id="p0053" num="0053">Those skilled in the art will recognize that a large number of "synthetic" non-natural nucleosides comprising various heterocyclic bases and various sugar moieties (and sugar analogs) are available in the art, and that as long as other criteria of the present invention are<!-- EPO <DP n="20"> --> satisfied, the ISS can include one or several heterocyclic bases other than the principal five base components of naturally-occurring nucleic acids. Preferably, however, the heterocyclic base in the ISS includes, but is not limited to, uracil-5-yl, cytosin-5-yl, adenin-7-yl, adenin-8-yl, guanin-7-yl, guanin-8-yl, 4-aminopyrrolo [2.3-d] pyrimidin-5-yl, 2-amino-4-oxopyrolo [2,3-d] pyrimidin-5-yl, 2-amino-4-oxopyrrolo [2.3-d] pyrimidin-3-yl groups, where the purines are attached to the sugar moiety of the ISS via the 9-position, the pyrimidines via the 1-position, the pyrrolopyrimidines via the 7-position and the pyrazolopyrimidines via the 1-position.</p><p id="p0054" num="0054">The ISS may comprise at least one modified base. As used herein, the term "modified base" is synonymous with "base analog," for example, "modified cytosine" is synonymous with "cytosine analog." Similarly, "modified" nucleosides or nucleotides are herein defined as being synonymous with nucleoside or nucleotide "analogs." Examples of base modifications include, but are not limited to, addition of an electron-withdrawing moiety to C-5 and/or C-6 of a cytosine of the ISS. Preferably, the electron-withdrawing moiety is a halogen. Such modified cytosines can include, but are not limited to, azacytosine, 5-bromocytosine, bromouracil, 5-chlorocytosine, chlorinated cytosine, cyclocytosine, cytosine arabinoside, 5-fluorocytosine, fluoropyrimidine, fluorouracil, 5,6-dihydrocytosine, 5-iodocytosine, hydroxyurea, iodouracil, 5-nitrocytosine, uracil, and any other pyrimidine analog or modified pyrimidine. Other examples of base modifications include, but are not limited to, addition of an electron-withdrawing moiety to C-5 and/or C-6 of a uracil of the ISS. Preferably, the electron-withdrawing moiety is a halogen. Such modified uracils can include, but are not limited to, 5-bromouracil, 5-chlorouracil, 5-fluorouracil, and 5-iodouracil.</p><p id="p0055" num="0055">Other examples of base modifications include the addition of one or more thiol groups to the base including, but not limited to, 2-amino-adenine, 6-thio-guanine, 2-thio-thymine, 4-thio-thymine, 5-propynyl-uracil, and 4-thio-uracil. Other examples of base modifications include, but are not limited to, N4-ethylcytosine, 7-deazaguanine, 7-deaza-8-azaguanine and 5-hydroxycytosine. See, for example,<nplcit id="ncit0052" npl-type="s"><text> Kandimalla et al. (2001) Bioorg. Med. Chem. 9:807-813</text></nplcit>.</p><p id="p0056" num="0056">The preparation of base-modified nucleosides, and the synthesis of modified oligonucleotides using said base-modified nucleosides as precursors, has been described, for example, in <patcit id="pcit0023" dnum="US4910300A"><text>U.S. Patents 4,910,300</text></patcit>, <patcit id="pcit0024" dnum="US4948882A"><text>4,948,882</text></patcit>, and <patcit id="pcit0025" dnum="US5093232A"><text>5,093,232</text></patcit>. These base-modified nucleosides<!-- EPO <DP n="21"> --> have been designed so that they can be incorporated by chemical synthesis into either terminal or internal positions of an oligonucleotide. Such base-modified nucleosides, present at either terminal or internal positions of an oligonucleotide, can serve as sites for attachment of a peptide or other antigen. Nucleosides modified in their sugar moiety have also been described (including, but not limited to, e.g., <patcit id="pcit0026" dnum="US4849513A"><text>U.S. Patent Nos. 4,849,513</text></patcit>; <patcit id="pcit0027" dnum="US5015733A"><text>5,015,733</text></patcit>; <patcit id="pcit0028" dnum="US5118800A"><text>5,118,800</text></patcit>; and <patcit id="pcit0029" dnum="US5118802A"><text>5,118,802</text></patcit>) and can be used similarly.</p><p id="p0057" num="0057">In some embodiments, an ISS is less than about any of the following lengths (in bases or base pairs): 10,000; 5,000; 2500; 2000; 1500; 1250; 1000; 750; 500; 300; 250; 200; 175; 150; 125; 100; 75; 60; 50; 40; 30; 25; 20; 15; 14; 13; 12; 11; 10. In some embodiments, an ISS is greater than about any of the following lengths (in bases or base pairs): 10; 11; 12; 13; 14; 15; 20; 25; 30; 40; 50; 60; 75; 100; 125; 150; 175; 200; 250; 300; 350; 400; 500; 750; 1000; 2000; 5000; 7500; 10000; 20000; 50000. Alternately, the ISS can be any of a range of sizes having an upper limit of 10,000; 5,000; 2500; 2000; 1500; 1250; 1000; 750; 500; 300; 250; 200; 175; 150; 125; 100; 75; 60; 50; 40; 30; 25; 20; 15; 14; 13; 12; 11; 10 and an independently selected lower limit of 10; 11; 12; 13; 14; 15; 20; 25; 30; 40; 50; 60; 75; 100; 125; 150; 175; 200; 250; 300; 350; 400; 500; 750; 1000; 2000; 5000; 7500, wherein the lower limit is less than the upper limit. In some embodiments, an ISS is preferably about 200 or less bases in length.</p><p id="p0058" num="0058">Alternatively, ISS may be isolated from microbial species (especially mycobacteria) using techniques well-known in the art, such as nucleic acid hybridization. Preferably, such isolated ISS will be purified to a substantially pure state, i.e., to be free of endogenous contaminants, such as lipopolysaccharides. ISS isolated as part of a larger polynucleotide can be reduced to the desired length by techniques well known in the art, such as by endonuclease digestion. Those of ordinary skill in the art will be familiar with, or can readily ascertain, techniques suitable for isolation, purification and digestion of polynucleotides to obtain ISS of potential use in the invention.</p><p id="p0059" num="0059">Confirmation that a particular oligonucleotide has the properties of an ISS useful in the invention can be obtained by evaluating whether the ISS affects cytokine secretion as described in <i>infra.</i> Details of in vitro techniques useful in making such an evaluation are given in the Examples; those of ordinary skill in the art will also know of, or can readily ascertain, other methods for measuring cytokine secretion along the parameters taught herein.<!-- EPO <DP n="22"> --></p><heading id="h0012"><u>Antigen that May be Administered with ISS</u></heading><p id="p0060" num="0060">We also describe that antigen may be co-administered with an ISS and/or used in compositions comprising an ISS and antigen (and preparation of these compositions).</p><p id="p0061" num="0061">The antigen may be an allergen. Examples of recombinant allergens are provided in Table 1. Preparation of many allergens is well-known in the art, including, but not limited to, preparation of ragweed pollen allergen Antigen E (Amb a I) (<nplcit id="ncit0053" npl-type="s"><text>Rafnar et al. (1991) J. Biol. Chem. 266:1229-1236</text></nplcit>), grass allergen Lol p 1 (<nplcit id="ncit0054" npl-type="s"><text>Tamborini et al. (1997) Eur. J. Biochem. 249:886-894</text></nplcit>), major dust mite allergens Der pI and Der PII (<nplcit id="ncit0055" npl-type="s"><text>Chua et al. (1988) J. Exp. Med. 167:175-182</text></nplcit>; <nplcit id="ncit0056" npl-type="s"><text>Chua et al. (1990) Int. Arch. Allergy Appl. Immunol. 91:124-129</text></nplcit>), domestic cat allergen Fel d I (<nplcit id="ncit0057" npl-type="s"><text>Rogers et al. (1993) Mol. Immunol. 30:559-568</text></nplcit>), white birch pollen Bet vl (<nplcit id="ncit0058" npl-type="s"><text>Breiteneder et al. (1989) EMBO J. 8:1935-1938</text></nplcit>), Japanese cedar allergens Cry j 1 and Cry j 2 (<nplcit id="ncit0059" npl-type="s"><text>Kingetsu et al. (2000) Immunology 99:625-629</text></nplcit>), and protein antigens from other tree pollen (<nplcit id="ncit0060" npl-type="s"><text>Elsayed et al. (1991) Scand. J. Clin. Lab. Invest. Suppl. 204:17-31</text></nplcit>). As indicated, allergens from trees are known, including allergens from birch, juniper and Japanese cedar. Preparation of protein antigens from grass pollen for <i>in vivo</i> administration has been reported.</p><p id="p0062" num="0062">The allergen may be a food allergen, including, but not limited to, peanut allergen, for example Ara h I (<nplcit id="ncit0061" npl-type="s"><text>Stanley et al. (1996) Adv. Exp. Med. Biol. 409:213-216</text></nplcit>); walnut allergen, for example, Jug r I (<nplcit id="ncit0062" npl-type="s"><text>Tueber et al. (1998) J. Allergy Clin. Immunol. 101:807-814</text></nplcit>); brazil nut allergen, for example, albumin (<nplcit id="ncit0063" npl-type="s"><text>Pastorello et al. (1998) J. Allergy Clin. Immunol. 102:1021-1027</text></nplcit>; shrISS allergen, for example, Pen a I (<nplcit id="ncit0064" npl-type="s"><text>Reese et al. (1997) Int. Arch. Allergy Immunol. 113:240-242</text></nplcit>); egg allergen, for example, ovomucoid (<nplcit id="ncit0065" npl-type="s"><text>Crooke et al. (1997) J. Immunol. 159:2026-2032</text></nplcit>); milk allergen, for example, bovine β-lactoglobin (<nplcit id="ncit0066" npl-type="s"><text>Selot al. (1999) Clin. Exp. Allergy 29:1055-1063</text></nplcit>); fish allergen, for example, parvalbumins (<nplcit id="ncit0067" npl-type="s"><text>Van Do et al. (1999) Scand. J. Immuuol. 50:619-625</text></nplcit>; <nplcit id="ncit0068" npl-type="s"><text>Galland et al. (1998) J. Chromatogr. B. Biomed. Sci. Appl. 706:63-71</text></nplcit>). In some embodiments, the allergen is a latex allergen, including but not limited to, Hev b 7 (<nplcit id="ncit0069" npl-type="s"><text>Sowka et al. (1998) Eur. J. Biochem. 255:213-219</text></nplcit>). Table 1 shows an exemplary list of allergens that may be used.<!-- EPO <DP n="23"> -->
<tables id="tabl0001" num="0001"><table frame="all"><title><b>TABLE 1</b></title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="55mm"/><colspec colnum="2" colname="col2" colwidth="56mm"/><colspec colnum="3" colname="col3" colwidth="55mm"/><thead><row><entry namest="col1" nameend="col3" align="center" valign="middle"><b><i>RECOMBINANT ALLERGENS</i></b></entry></row><row><entry align="center" valign="middle"><b>Group</b></entry><entry align="center" valign="middle"><b>Allergen</b></entry><entry align="center" valign="middle"><b>Reference</b></entry></row><row><entry align="center" valign="middle"><b>ANIMALS:</b></entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry align="center" valign="middle"><b>CRUSTACEA</b></entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row></thead><tbody><row><entry morerows="1" rowsep="1" align="center" valign="middle">ShrISS/lobster</entry><entry morerows="1" rowsep="1" align="center" valign="middle">tropomyosin Pan s I</entry><entry align="center" valign="middle"><nplcit id="ncit0070" npl-type="s"><text>Leung et al. (1996) J. Allergy Clin. Immunol. 98:954-961</text></nplcit></entry></row><row><entry align="center" valign="middle"><nplcit id="ncit0071" npl-type="s"><text>Leung et al. (1998) Mol. Mar. Biol. Biotechnol. 7:12-20</text></nplcit></entry></row></tbody></tgroup><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="55mm"/><colspec colnum="2" colname="col2" colwidth="56mm"/><colspec colnum="3" colname="col3" colwidth="55mm"/><thead><row><entry align="center" valign="middle"><b>INSECTS</b></entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row></thead><tbody><row><entry align="center" valign="middle">Ant</entry><entry align="center" valign="middle">Sol i 2 (venom)</entry><entry align="center" valign="middle"><nplcit id="ncit0072" npl-type="s"><text>Schmidt et al. J Allergy Clin Immunol., 1996, 98:82-8</text></nplcit></entry></row><row><entry morerows="4" rowsep="1" align="center" valign="middle">Bee</entry><entry align="center" valign="middle">Phospholipase A2 (PLA)</entry><entry align="center" valign="middle"><nplcit id="ncit0073" npl-type="s"><text>Muller et al. J Allergy Clin Immunol, 1995, 96:395-402</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"><nplcit id="ncit0074" npl-type="s"><text>Forster et al. J Allergy Clin Immunol, 1995, 95:1229-35</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"><nplcit id="ncit0075" npl-type="s"><text>Muller et al. Clin Exp Allergy, 1997, 27:915-20</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry align="center" valign="middle">Hyaluronidase (Hya)</entry><entry align="center" valign="middle"><nplcit id="ncit0076" npl-type="s"><text>Soldatova et al. J Allergy Clin Immunol, 1998, 101:691-8</text></nplcit></entry></row><row><entry morerows="4" rowsep="1" align="center" valign="middle">Cockroach</entry><entry align="center" valign="middle">Bla g Bd90K</entry><entry align="center" valign="middle"><nplcit id="ncit0077" npl-type="s"><text>Helm et al. J Allergy Clin Immunol, 1996, 98:172-180</text></nplcit></entry></row><row><entry align="center" valign="middle">Bla g 4 (a calycin)</entry><entry align="center" valign="middle"><nplcit id="ncit0078" npl-type="s"><text>Vailes et al. J Allergy Clin Immunol, 1998, 101:274-280</text></nplcit></entry></row><row><entry align="center" valign="middle">Glutathione S-transferase</entry><entry align="center" valign="middle"><nplcit id="ncit0079" npl-type="s"><text>Arruda et al. J Biol Chem, 1997, 272:20907-12</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry align="center" valign="middle">Per a 3</entry><entry align="center" valign="middle"><nplcit id="ncit0080" npl-type="s"><text>Wu et al. Mol Immunol, 1997, 34:1-8</text></nplcit></entry></row><row><entry morerows="13" rowsep="1" align="center" valign="middle">Dust mite</entry><entry align="center" valign="middle">Der p 2 (major allergen)</entry><entry align="center" valign="middle"><nplcit id="ncit0081" npl-type="s"><text>Lynch et al. J Allergy Clin Immunol, 1998, 101:562-4</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"><nplcit id="ncit0082" npl-type="s"><text>Hakkaart et al. Clin Exp Allergy, 1998, 28:169-74</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"><nplcit id="ncit0083" npl-type="s"><text>Hakkaart et al. Clin Exp Allergy, 1998, 28:45-52</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"><nplcit id="ncit0084" npl-type="s"><text>Hakkaart et al. Int Arch Allergy Immunol, 1998, 115 (2):150-6</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"><nplcit id="ncit0085" npl-type="s"><text>Mueller et al. J Biol Chem, 1997, 272:26893-8</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry align="center" valign="middle">Der p2 variant</entry><entry align="center" valign="middle"><nplcit id="ncit0086" npl-type="s"><text>Smith et al. J Allergy Clin Immunol, 1998, 101:423-5</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry align="center" valign="middle">Der f2</entry><entry align="center" valign="middle"><nplcit id="ncit0087" npl-type="s"><text>Yasue et al. Clin Exp Immunol, 1998, 113:1-9</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"><nplcit id="ncit0088" npl-type="s"><text>Yasue et al. Cell Immunol, 1997, 181:30-7</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry align="center" valign="middle">Der p10</entry><entry align="center" valign="middle"><nplcit id="ncit0089" npl-type="s"><text>Asturias et al. Biochim Biophys Acta, 1998, 1397:27-30</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry align="center" valign="middle">Tyr p 2</entry><entry align="center" valign="middle"><nplcit id="ncit0090" npl-type="s"><text>Eriksson et al. Eur J Biochem, 1998</text></nplcit></entry></row><row><entry align="center" valign="middle">Hornet</entry><entry align="center" valign="middle">Antigen 5 aka Dol m V (venom)</entry><entry align="center" valign="middle"><nplcit id="ncit0091" npl-type="s"><text>Tomalski et al. Arch Insect Biochem Physiol, 1993, 22:303-13</text></nplcit></entry></row><row><entry align="center" valign="middle">Mosquito</entry><entry align="center" valign="middle">Aed a I (salivary apyrase)</entry><entry align="center" valign="middle"><nplcit id="ncit0092" npl-type="s"><text>Xu et al. Int Arch Allergy Immunol, 1998, 115:245-51</text></nplcit></entry></row><!-- EPO <DP n="24"> --><row><entry align="center" valign="middle">Yellow jacket</entry><entry align="center" valign="middle">antigen 5, hyaluronidase and phospholipase (venom)</entry><entry align="center" valign="middle"><nplcit id="ncit0093" npl-type="s"><text>King et al. J Allergy Clin Immunol, 1996, 98:588-600</text></nplcit></entry></row></tbody></tgroup><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="55mm"/><colspec colnum="2" colname="col2" colwidth="56mm"/><colspec colnum="3" colname="col3" colwidth="55mm"/><thead><row><entry align="center" valign="middle"><b>MAMMALS</b></entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row></thead><tbody><row><entry morerows="2" rowsep="1" align="center" valign="middle">Cat</entry><entry align="center" valign="middle"/><entry align="center" valign="middle"><nplcit id="ncit0094" npl-type="s"><text>Slunt et al. J Allergy Clin Immunol, 1995, 95:1221-8</text></nplcit></entry></row><row><entry align="center" valign="middle">Fel d I</entry><entry align="center" valign="middle"><nplcit id="ncit0095" npl-type="s"><text>Hoffmann et al. (1997) J Allergy Clin Immunol 99:227-32</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"><nplcit id="ncit0096" npl-type="s"><text>Hedlin Curr Opin Pediatr, 1995, 7:676-82</text></nplcit></entry></row><row><entry morerows="4" rowsep="1" align="center" valign="middle">Cow</entry><entry morerows="1" align="center" valign="middle">Bos d 2 (dander; a lipocalin)</entry><entry align="center" valign="middle"><nplcit id="ncit0097" npl-type="s"><text>Zeiler et al. J Allergy Clin Immunol, 1997, 100:721-7</text></nplcit></entry></row><row><entry align="center" valign="middle"><nplcit id="ncit0098" npl-type="s"><text>Rautiainen et al. Biochem Bioph. Res Comm., 1998, 247:746-50</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry morerows="1" rowsep="1" align="center" valign="middle">ß-lactoglobulin (BLG, major cow milk allergen)</entry><entry align="center" valign="middle"><nplcit id="ncit0099" npl-type="s"><text>Chatel et al. Mol Immunol, 1996, 33:1113-8</text></nplcit></entry></row><row><entry align="center" valign="middle"><nplcit id="ncit0100" npl-type="s"><text>Lehrer et al. Crit Rev Food Sci Nutr, 1996, 36:553-64</text></nplcit></entry></row><row><entry morerows="2" rowsep="1" align="center" valign="middle">Dog</entry><entry morerows="2" rowsep="1" align="center" valign="middle">Can f I and Can f 2, salivary lipocalins</entry><entry align="center" valign="middle"><nplcit id="ncit0101" npl-type="s"><text>Konieczny ct al. Immunology, 1997, 92:577-86</text></nplcit></entry></row><row><entry align="center" valign="middle"><nplcit id="ncit0102" npl-type="s"><text>Spitzauer et al. J Allergy Clin Immunol, 1994, 93:614-27</text></nplcit></entry></row><row><entry align="center" valign="middle"><nplcit id="ncit0103" npl-type="s"><text>Vrtala et al. J Immunol, 1998, 160:6137-44</text></nplcit></entry></row><row><entry align="center" valign="middle">Horse</entry><entry align="center" valign="middle">Equ c1 (major allergen, a lipocalin)</entry><entry align="center" valign="middle"><nplcit id="ncit0104" npl-type="s"><text>Gregoire et al. J Biol Chem, 1996, 271:32951-9</text></nplcit></entry></row><row><entry align="center" valign="middle">Mouse</entry><entry align="center" valign="middle">mouse urinary protein (MUP)</entry><entry align="center" valign="middle"><nplcit id="ncit0105" npl-type="s"><text>Konieczny et al. Immunology, 1997, 92:577-86</text></nplcit></entry></row><row><entry align="center" valign="middle"><b>OTHER MAMMALIAN ALLERGENS</b></entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry morerows="2" rowsep="1" align="center" valign="middle">Insulin</entry><entry morerows="2" rowsep="1" align="center" valign="middle"/><entry align="center" valign="middle"><nplcit id="ncit0106" npl-type="s"><text>Ganz et al. J Allergy Clin Immunol, 1990, 86:45-51</text></nplcit></entry></row><row><entry align="center" valign="middle"><nplcit id="ncit0107" npl-type="s"><text>Grammer et al. J Lab Clin Med, 1987,109:141-6</text></nplcit></entry></row><row><entry align="center" valign="middle"><nplcit id="ncit0108" npl-type="s"><text>Gonzalo et al. Allergy, 1998, 53:106-7</text></nplcit></entry></row><row><entry align="center" valign="middle">Interferons</entry><entry align="center" valign="middle">interferon alpha 2c</entry><entry align="center" valign="middle"><nplcit id="ncit0109" npl-type="s"><text>Detmar et al. Contact Dermatis, 1989, 20:149-50</text></nplcit></entry></row><row><entry align="center" valign="middle"><b>MOLLUSCS</b></entry><entry align="center" valign="middle">topomyosin</entry><entry align="center" valign="middle"><nplcit id="ncit0110" npl-type="s"><text>Leung et al. J Allergy Clin Immunol, 1996, 98:954-61</text></nplcit></entry></row></tbody></tgroup><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="55mm"/><colspec colnum="2" colname="col2" colwidth="56mm"/><colspec colnum="3" colname="col3" colwidth="55mm"/><thead><row><entry align="center" valign="middle"><b>PLANT ALLERGENS:</b></entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row></thead><tbody><row><entry align="center" valign="middle">Barley</entry><entry align="center" valign="middle">Hor v 9</entry><entry align="center" valign="middle"><nplcit id="ncit0111" npl-type="s"><text>Astwood et al. Adv Exp Med Biol, 1996, 409:269-77</text></nplcit></entry></row><row><entry morerows="7" rowsep="1" align="center" valign="middle">Birch</entry><entry align="center" valign="middle"/><entry morerows="1" align="center" valign="middle"><nplcit id="ncit0112" npl-type="s"><text>Twardosz et al. Biochem Bioph. Res Comm., 1997, 23 9:197</text></nplcit></entry></row><row><entry align="center" valign="middle">pollen allergen, Bet v 4</entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"><nplcit id="ncit0113" npl-type="s"><text>Pauli et al. J Allergy Clin Immunol, 1996, 97:1100-9</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"><nplcit id="ncit0114" npl-type="s"><text>van Neerven et al. Clin Exp Allergy, 1998, 28:423-33</text></nplcit></entry></row><row><entry morerows="1" align="center" valign="middle">rBet v 1 Bet v 2: (profilin)</entry><entry align="center" valign="middle"><nplcit id="ncit0115" npl-type="s"><text>Jahn-Schmid et al. Immunotechnology, 1996, 2:103-13</text></nplcit></entry></row><row><entry align="center" valign="middle"><nplcit id="ncit0116" npl-type="s"><text>Breitwieser et al. Biotechniques, 1996, 21:918-25</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"><nplcit id="ncit0117" npl-type="s"><text>Fuchs et al. J Allergy Clin Immunol, 1997, 100:3 56-64</text></nplcit></entry></row><row><entry align="center" valign="middle">Brazil nut</entry><entry align="center" valign="middle">globulin</entry><entry align="center" valign="middle"><nplcit id="ncit0118" npl-type="s"><text>Bartolome et al. Allergol Immunopathol, 1997,25:135-44</text></nplcit></entry></row><!-- EPO <DP n="25"> --><row><entry align="center" valign="middle">Cherry</entry><entry align="center" valign="middle">Pru a I (major allergen)</entry><entry align="center" valign="middle"><nplcit id="ncit0119" npl-type="s"><text>Scheurer et al. Mol Immunol, 1997, 34:619-29</text></nplcit></entry></row><row><entry morerows="1" rowsep="1" align="center" valign="middle">Corn</entry><entry morerows="1" rowsep="1" align="center" valign="middle">Zml3 (pollen)</entry><entry align="center" valign="middle"><nplcit id="ncit0120" npl-type="s"><text>Heiss et al. FEBS Lett, 1996, 381:217-21</text></nplcit></entry></row><row><entry align="center" valign="middle"><nplcit id="ncit0121" npl-type="s"><text>Lehrer et al. Int Arch Allergy Immunol, 1997, 113:122-4</text></nplcit></entry></row><row><entry morerows="11" rowsep="1" align="center" valign="middle">Grass</entry><entry morerows="2" align="center" valign="middle">Phl p 1, Phl p 2, Phl p 5 (timothy grass pollen)</entry><entry align="center" valign="middle"><nplcit id="ncit0122" npl-type="s"><text>Bufe et al. Am J Respir Crit Care Med, 1998, 157:1269-76</text></nplcit></entry></row><row><entry align="center" valign="middle"><nplcit id="ncit0123" npl-type="s"><text>Vrtala et al. J Immunol Jun 15, 1998, 160:6137-44</text></nplcit></entry></row><row><entry align="center" valign="middle"><nplcit id="ncit0124" npl-type="s"><text>Niederberger et al. J Allergy Clin Immun., 1998, 101:258-64</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry morerows="1" align="center" valign="middle">Hol 1 5 velvet grass pollen</entry><entry align="center" valign="middle"><nplcit id="ncit0125" npl-type="s"><text>Schramm et al. Eur J Biochem, 1998, 252:200-6</text></nplcit></entry></row><row><entry align="center" valign="middle"/></row><row><entry morerows="1" align="center" valign="middle">Bluegrass allergen</entry><entry align="center" valign="middle"><nplcit id="ncit0126" npl-type="s"><text>Zhang et al. J Immunol, 1993, 151:791-9</text></nplcit></entry></row><row><entry align="center" valign="middle"/></row><row><entry morerows="1" align="center" valign="middle">Cyn d 7 Bermuda grass</entry><entry align="center" valign="middle"><nplcit id="ncit0127" npl-type="s"><text>Smith et al. Int Arch Allergy Immunol, 1997, 114:265-71</text></nplcit></entry></row><row><entry align="center" valign="middle"/></row><row><entry morerows="1" rowsep="1" align="center" valign="middle">Cyn d 12 (a profilin)</entry><entry align="center" valign="middle"><nplcit id="ncit0128" npl-type="s"><text>Asturias et al. Clin Exp Allergy, 1997, 27:1307-13</text></nplcit></entry></row><row><entry align="center" valign="middle"><nplcit id="ncit0129" npl-type="s"><text>Fuchs et al. J Allergy Clin Immunol, 1997, 100:356-64</text></nplcit></entry></row><row><entry morerows="3" rowsep="1" align="center" valign="middle">Japanese Cedar</entry><entry align="center" valign="middle">Jun a 2 (Juniperus ashei)</entry><entry align="center" valign="middle"><nplcit id="ncit0130" npl-type="s"><text>Yokoyama et al. Biochem. Biophys. Res. Commun., 2000, 275:195-202</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"><nplcit id="ncit0131" npl-type="s"><text>Kingetsu et al. Immunology, 2000, 99:625-629</text></nplcit></entry></row><row><entry align="center" valign="middle">Cry j 1, Cry j 2 (Cryptomeria japonica)</entry><entry align="center" valign="middle"/></row><row><entry align="center" valign="middle">Juniper</entry><entry align="center" valign="middle">Jun o 2 (pollen)</entry><entry align="center" valign="middle"><nplcit id="ncit0132" npl-type="s"><text>Tinghino et al. J Allergy Clin Immunol, 1998, 101:772-7</text></nplcit></entry></row><row><entry morerows="1" rowsep="1" align="center" valign="middle">Latex</entry><entry morerows="1" rowsep="1" align="center" valign="middle">Hev b 7</entry><entry align="center" valign="middle"><nplcit id="ncit0133" npl-type="s"><text>Sowka et al. Eur J Biochem, 1998, 255:213-9</text></nplcit></entry></row><row><entry align="center" valign="middle"><nplcit id="ncit0134" npl-type="s"><text>Fuchs et al. J Allergy Clin Immunol, 1997, 100:3 56-64</text></nplcit></entry></row><row><entry align="center" valign="middle">Mercurialis</entry><entry align="center" valign="middle">Mer a I (profilin)</entry><entry align="center" valign="middle"><nplcit id="ncit0135" npl-type="s"><text>Vallverdu et al. J Allergy Clin Immunol, 1998, 101:3 63-70</text></nplcit></entry></row><row><entry align="center" valign="middle">Mustard (Yellow)</entry><entry align="center" valign="middle">Sin a I (seed)</entry><entry align="center" valign="middle"><nplcit id="ncit0136" npl-type="s"><text>Gonzalez de la Pena et al. Biochem Bioph. Res Comm., 1993, 190:648-53</text></nplcit></entry></row><row><entry align="center" valign="middle">Oilseed rape</entry><entry align="center" valign="middle">Bra r I pollen allergen</entry><entry align="center" valign="middle"><nplcit id="ncit0137" npl-type="s"><text>Smith et al. Int Arch Allergy Immunol, 1997, 114:265-71</text></nplcit></entry></row><row><entry morerows="2" rowsep="1" align="center" valign="middle">Peanut</entry><entry morerows="2" rowsep="1" align="center" valign="middle">Ara h I</entry><entry align="center" valign="middle"><nplcit id="ncit0138" npl-type="s"><text>Stanley ct al. Adv Exp Mcd Biol, 1996, 409:213-6</text></nplcit></entry></row><row><entry align="center" valign="middle"><nplcit id="ncit0139" npl-type="s"><text>Burks et al. J Clin Invest, 1995, 96:1715-21</text></nplcit></entry></row><row><entry align="center" valign="middle"><nplcit id="ncit0140" npl-type="s"><text>Burks et al. Int Arch Allergy Immunol, 1995, 107:248-50</text></nplcit></entry></row><row><entry morerows="1" rowsep="1" align="center" valign="middle">Poa pratensis</entry><entry morerows="1" rowsep="1" align="center" valign="middle">Poa p9</entry><entry align="center" valign="middle"><nplcit id="ncit0141" npl-type="s"><text>Parronchi et al. Eur J Immunol, 1996, 26:697-703</text></nplcit></entry></row><row><entry align="center" valign="middle"><nplcit id="ncit0142" npl-type="s"><text>Astwood ct al. Adv Exp Med Biol, 1996, 409:269-77</text></nplcit></entry></row><row><entry morerows="2" rowsep="1" align="center" valign="middle">Ragweed</entry><entry morerows="2" rowsep="1" align="center" valign="middle">Amb a I</entry><entry align="center" valign="middle"><nplcit id="ncit0143" npl-type="s"><text>Sun et al. Biotechnology Aug, 1995, 13:779-86</text></nplcit></entry></row><row><entry align="center" valign="middle"><nplcit id="ncit0144" npl-type="s"><text>Hirschwehr et al. J Allergy Clin Immunol, 1998, 101:196-206</text></nplcit></entry></row><row><entry align="center" valign="middle"><nplcit id="ncit0145" npl-type="s"><text>Casale et al. J Allergy Clin Immunol, 1997, 100:110-21</text></nplcit></entry></row><row><entry align="center" valign="middle">Rye</entry><entry align="center" valign="middle">Lol p I</entry><entry align="center" valign="middle"><nplcit id="ncit0146" npl-type="s"><text>Tamborini et al. Eur J Biochem, 1997, 249:886-94</text></nplcit></entry></row><!-- EPO <DP n="26"> --><row><entry align="center" valign="middle">Walnut</entry><entry align="center" valign="middle">Jug r I</entry><entry align="center" valign="middle"><nplcit id="ncit0147" npl-type="s"><text>Teuber et al. J Allergy Clin Immun., 1998, 101:807-14</text></nplcit></entry></row><row><entry morerows="1" rowsep="1" align="center" valign="middle">Wheat</entry><entry morerows="1" rowsep="1" align="center" valign="middle">allergen</entry><entry align="center" valign="middle"><nplcit id="ncit0148" npl-type="s"><text>Fuchs et al. J Allergy Clin Immunol, 1997, 100:356-64</text></nplcit></entry></row><row><entry align="center" valign="middle"><nplcit id="ncit0149" npl-type="s"><text>Donovan et al. Electrophoresis, 1993, 14:917-22</text></nplcit></entry></row></tbody></tgroup><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="55mm"/><colspec colnum="2" colname="col2" colwidth="56mm"/><colspec colnum="3" colname="col3" colwidth="55mm"/><thead><row><entry align="center" valign="middle"><b>FUNGI:</b></entry><entry align="center" valign="middle"/><entry align="center" valign="middle"/></row></thead><tbody><row><entry morerows="7" rowsep="1" align="center" valign="middle">Aspergillus</entry><entry morerows="1" align="center" valign="middle">Asp f 1, Asp f 2, Asp f3, Asp f 4, rAsp f 6</entry><entry align="center" valign="middle"><nplcit id="ncit0150" npl-type="s"><text>Crameri et al. Mycoses, 1998, 41 Suppl 1:56-60</text></nplcit></entry></row><row><entry align="center" valign="middle"><nplcit id="ncit0151" npl-type="s"><text>Hemmann et al. Eur J Immunol, 1998, 28:1155-60</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"><nplcit id="ncit0152" npl-type="s"><text>Banerjee et al. J Allergy Clin Immunol, 1997, 99:821-7</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"><nplcit id="ncit0153" npl-type="s"><text>Crameri Int Arch Allergy Immunol, 1998, 115:99-114</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"><nplcit id="ncit0154" npl-type="s"><text>Crameri et al. Adv Exp Med Biol, 1996, 409:111-6</text></nplcit></entry></row><row><entry align="center" valign="middle"/><entry align="center" valign="middle"><nplcit id="ncit0155" npl-type="s"><text>Moser et al. J Allergy Clin Immunol, 1994, 93: 1-11</text></nplcit></entry></row><row><entry morerows="1" rowsep="1" align="center" valign="middle">Manganese superoxide dismutase (MNSOD)</entry><entry align="center" valign="middle"/></row><row><entry align="center" valign="middle"><nplcit id="ncit0156" npl-type="s"><text>Mayer et al. Int Arch Allergy Immunol, 1997, 113:213-5</text></nplcit></entry></row><row><entry align="center" valign="middle">Blomia</entry><entry align="center" valign="middle">allergen</entry><entry align="center" valign="middle"><nplcit id="ncit0157" npl-type="s"><text>Caraballo ct al. Adv Exp Mcd Biol, 1996, 409:81-3</text></nplcit></entry></row><row><entry align="center" valign="middle">Penicillinium</entry><entry align="center" valign="middle">allergen</entry><entry align="center" valign="middle"><nplcit id="ncit0158" npl-type="s"><text>Shen et al. Clin Exp Allergy, 1997, 27:682-90</text></nplcit></entry></row><row><entry align="center" valign="middle">Psilocybe</entry><entry align="center" valign="middle">Psi c 2</entry><entry align="center" valign="middle"><nplcit id="ncit0159" npl-type="s"><text>Horner et al. Int Arch Allergy Immunol, 1995, 107:298-300</text></nplcit></entry></row></tbody></tgroup></table></tables></p><p id="p0063" num="0063">The antigen may be from an infectious agent, including protozoan, bacterial, fungal (including unicellular and multicellular), and viral infectious agents. Examples of suitable viral antigens are described herein and are known in the art. Bacteria include <i>Hemophilus influenza, Mycobacterium tuberculosis</i> and <i>Bordetella pertussis.</i> Protozoan infectious agents include malarial plasmodia, <i>Leishmania</i> species, <i>Trypanosoma</i> species and <i>Schistosoma</i> species. Fungi include <i>Candida albicans.</i></p><p id="p0064" num="0064">The antigen may be a viral antigen. Viral polypeptide antigens include, but are not limited to, HIV proteins such as HIV gag proteins (including, but not limited to, membrane anchoring (MA) protein, core capsid (CA) protein and nucleocapsid (NC) protein), HIV polymerase, influenza virus matrix (M) protein and influenza virus nucleocapsid (NP) protein, hepatitis B surface antigen (HBsAg), hepatitis B core protein (HBcAg), hepatitis e protein (HBeAg), hepatitis B DNA polymerase, hepatitis C antigens, and the like. References discussing influenza vaccination include <nplcit id="ncit0160" npl-type="s"><text>Scherle and Gerhard (1988) Proc. Natl. Acad. Sci. USA 85:4446-4450</text></nplcit>; <nplcit id="ncit0161" npl-type="s"><text>Scherle and Gerhard (1986) J. Exp. Med. 164:1114-1128</text></nplcit>; <nplcit id="ncit0162" npl-type="s"><text>Granoff et al. (1993) Vaccine 11:S46-51</text></nplcit>;<nplcit id="ncit0163" npl-type="s"><text> Kodihalli et al. (1997) J. Virol. 71:3391-3396</text></nplcit>; <nplcit id="ncit0164" npl-type="s"><text>Ahmeida et al. (1993) Vaccine 11:1302-1309</text></nplcit>; <nplcit id="ncit0165" npl-type="s"><text>Chen et al. (1999) Vaccine 17:653-659</text></nplcit>; <nplcit id="ncit0166" npl-type="s"><text>Govorkova and Smirnov (1997)<!-- EPO <DP n="27"> --> Acta Virol. (1997) 41:251-257</text></nplcit>; <nplcit id="ncit0167" npl-type="s"><text>Koide et al. (1995) Vaccine 13:3-5</text></nplcit>; <nplcit id="ncit0168" npl-type="s"><text>Mbawuike et al. (1994) Vaccine 12:1340-1348</text></nplcit>; <nplcit id="ncit0169" npl-type="s"><text>Tamura et al. (1994) Vaccine 12:310-316</text></nplcit>; <nplcit id="ncit0170" npl-type="s"><text>Tamura et al. (1992) Eur. J. Immunol. 22:477-481</text></nplcit>; <nplcit id="ncit0171" npl-type="s"><text>Hirabayashi et al. (1990) Vaccine 8:595-599</text></nplcit>. Other examples of antigen polypeptides are group- or sub-group specific antigens, which are known for a number of infectious agents, including, but not limited to, adenovirus, herpes simplex virus, papilloma virus, respiratory syncytial virus and poxviruses.</p><p id="p0065" num="0065">Many antigenic peptides and proteins are known, and available in the art; others can be identified using conventional techniques. For immunization against tumor formation or treatment of existing tumors, immunomodulatory peptides can include tumor cells (live or irradiated), tumor cell extracts, or protein subunits of tumor antigens such as Her-2/neu, Mart1, carcinoembryonic antigen (CEA), gangliosides, human milk fat globule (HMFG), mucin (MUC1), MAGE antigens, BAGE antigens, GAGE antigens, gp100, prostate specific antigen (PSA), and tyrosinase. Vaccines for immuno-based contraception can be formed by including sperm proteins administered with ISS. <nplcit id="ncit0172" npl-type="s"><text>Lea et al. (1996) Biochim. Biophys. Acta 1307:263</text></nplcit>.</p><p id="p0066" num="0066">Attenuated and inactivated viruses are suitable for use herein as the antigen. Preparation of these viruses is well-known in the art and many are commercially available (see, e.g., Physicians' Desk Reference (1998) 52nd edition, Medical Economics Company, Inc.). For example, polio virus is available as IPOL® (Pasteur Merieux Connaught) and ORIMUNE® (Lederle Laboratories), hepatitis A virus as VAQTA® (Merck), measles virus as ATTENUVAX® (Merck), mumps virus as MUMPSVAX® (Merck) and rubella virus as MERUVAX®II (Merck). Additionally, attenuated and inactivated viruses such as HIV-1, HIV-2, herpes simplex virus, hepatitis B virus, rotavirus, human and non-human papillomavirus and slow brain viruses can provide peptide antigens. In some embodiments, the antigen comprises a viral vector, such as vaccinia, adenovirus, and canary pox.</p><p id="p0067" num="0067">Antigens may be isolated from their source using purification techniques known in the art or, more conveniently, may be produced using recombinant methods. Antigenic peptides can include purified native peptides, synthetic peptides, recombinant proteins, crude protein extracts, attenuated or inactivated viruses, cells, micro-organisms, or fragments of such peptides. Immunomodulatory peptides can be native or synthesized chemically or enzymatically. Any method of chemical synthesis known in the art is suitable. Solution phase peptide synthesis can<!-- EPO <DP n="28"> --> be used to construct peptides of moderate size or, for the chemical construction of peptides, solid phase synthesis can be employed. <nplcit id="ncit0173" npl-type="s"><text>Atherton et al. (1981) Hoppe Seylers Z. Physiol. Chem. 362:833-839</text></nplcit>. Proteolytic enzymes can also be utilized to couple amino acids to produce peptides. <nplcit id="ncit0174" npl-type="b"><text>Kullmann (1987) Enzymatic Peptide Synthesis, CRC Press, Inc</text></nplcit>. Alternatively, the peptide can be obtained by using the biochemical machinery of a cell, or by isolation from a biological source. Recombinant DNA techniques can be employed for the production of peptides. <nplcit id="ncit0175" npl-type="b"><text>Hames et al. (1987) Transcription and Translation: A Practical Approach, IRL Press</text></nplcit>. Peptides can also be isolated using standard techniques such as affinity chromatography.</p><p id="p0068" num="0068">Preferably the antigens are peptides, lipids (e.g., sterols excluding cholesterol, fatty acids, and phospholipids), polysaccharides such as those used in <i>H. influenza</i> vaccines, gangliosides and glycoproteins. These can be obtained through several methods known in the art, including isolation and synthesis using chemical and enzymatic methods. In certain cases, such as for many sterols, fatty acids and phospholipids, the antigenic portions of the molecules are commercially available.</p><p id="p0069" num="0069">Examples of viral antigens useful in the subject compositions and methods using the compositions include, but are not limited to, HIV antigens. Such antigens include, but are not limited to, those antigens derived from HIV envelope glycoproteins including, but not limited to, gp160, gp120 and gp41. Numerous sequences for HIV genes and antigens are known. For example, the Los Alamos National Laboratory HIV Sequence Database collects, curates and annotates HIV nucleotide and amino acid sequences. This database is accessible via the internet and in a yearly publication, see Human Retroviruses and AIDS Compendium (for example, 2000 edition).</p><p id="p0070" num="0070">Antigens derived from infectious agents may be obtained using methods known in the art, for example, from native viral or bacterial extracts, from cells infected with the infectious agent, from purified polypeptides, from recombinantly produced polypeptides and/or as synthetic peptides.<!-- EPO <DP n="29"> --></p><heading id="h0013"><u>ISS/MC complexes</u></heading><p id="p0071" num="0071">ISSs may be administered in the form of ISS/microcarrier (ISS/MC) complexes.</p><p id="p0072" num="0072">Microcarriers can be less than about 150, 120 or 100 µm in size, more commonly less than about 50-60 µm in size, preferably less than about 10 µm in size, and are insoluble in pure water. Microcarriers are preferably biodegradable, although nonbiodegradable microcarriers are acceptable. Microcarriers are commonly solid phase, such as "beads" or other particles, although liquid phase microcarriers such as oil in water emulsions comprising a biodegradable polymers or oils are also contemplated. A wide variety of biodegradable and nonbiodegradable materials acceptable for use as microcarriers are known in the art.</p><p id="p0073" num="0073">Microcarriers for use are generally less than about 10 µm in size (<i>e.g</i>., have an average diameter of less than about 10 µm, or at least about 97% of the particles pass through a 10 µm screen filter), and include nanocarriers (<i>i.e</i>., carriers of less than about 1 µm size). Preferably, microcarriers are selected having sizes within an upper limit of about 9, 7, 5, 2, or 1 µm or 900, 800, 700, 600, 500, 400, 300, 250, 200, or 100 nm and an independently selected lower limit of about 4, 2, or 1 µm or about 800, 600, 500, 400, 300, 250, 200, 150, 100, 50, 25, or 10 nm, where the lower limit is less than the upper limit. The microcarriers may have a size of about 1.0-1.5 µm, about 1.0-2.0 µm or about 0.9-1.6 µm. The microcarriers may have a size of about 10 nm to about 5 µm or about 25 nm to about 4.5 µm, about 1 µm, about 1.2 µm, about 1.4 µm, about 1.5 µm, about 1.6 µm, about 1.8 µm, about 2.0 µm, about 2.5 µm or about 4.5 µm. When the microcarriers are nanocarriers, the nanocarriers may be about 25 to about 300 nm, 50 to about 200 nm, about 50 nm or about 200 nm.</p><p id="p0074" num="0074">Solid phase biodegradable microcarriers may be manufactured from biodegradable polymers including, but not limited to: biodegradable polyesters, such as poly(lactic acid),<!-- EPO <DP n="30"> --> poly(glycolic acid), and copolymers (including block copolymers) thereof, as well as block copolymers of poly(lactic acid) and poly(ethylene glycol); polyorthoesters such as polymers based on 3,9-diethylidene-2,4,8,10-tetraoxaspiro[5.5]undecane (DETOSU); polyanhydrides such as poly(anhydride) polymers based on relatively hydrophilic monomers such as sebacic acid; polyanhydride imides, such as polyanhydride polymers based on sebacic acid-derived monomers incorporating amino acids <i>(i.e.,</i> linked to sebacic acid by imide bonds through the amino-terminal nitrogen) such as glycine or alanine; polyanhydride esters; polyphosphazenes, especially poly(phosphazenes) which contain hydrolysis-sensitive ester groups which can catalyze degradation of the polymer backbone through generation of carboxylic acid groups (<nplcit id="ncit0176" npl-type="s"><text>Schacht et al., (1996) Biolechnol. Bioeng. 1996:102</text></nplcit>); and polyamides such as poly(lactic acid-co-lysine).</p><p id="p0075" num="0075">A wide variety of nonbiodegradable materials suitable for manufacturing microcarriers are also known, including, but not limited to polystyrene, polypropylene, polyethylene, silica, ceramic, polyacrylamide, dextran, hydroxyapatite, latex, gold, and ferromagnetic or paramagnetic materials. Certain embodiments exclude gold, latex, and/or magnetic beads. In certain embodiments, the microcarriers may be made of a first material (e.g., a magnetic material) encapsulated with a second material (e.g., polystyrene).</p><p id="p0076" num="0076">Solid phase microspheres are prepared using techniques known in the art. For example, they can be prepared by emulsion-solvent extraction/evaporation technique. Generally, in this technique, biodegradable polymers such as polyanhydrates, poly(alkyl-α-cyanoacrylates) and poly(α-hydroxy esters), for example, poly(lactic acid), poly(glycolic acid), poly(D,L-lactic-co-glycolic acid) and poly(caprolactone), are dissolved in a suitable organic solvent, such as methylene chloride, to constitute the dispersed phase (DP) of emulsion. DP is emulsified by high-speed homogenization into excess volume of aqueous continuous phase (CP) that contains a dissolved surfactant, for example, polyvinylalcohol (PVA) or polyvinylpirrolidone (PVP). Surfactant in CP is to ensure the formation of discrete and suitably-sized emulsion droplet. The organic solvent is then extracted into the CP and subsequently evaporated by raising the system temperature. The solid microparticles are then separated by centrifugation or filtration, and dried, for example, by lyophilization or application of vaccum, before storing at 4 °C.<!-- EPO <DP n="31"> --></p><p id="p0077" num="0077">Physico-chemical characteristics such as mean size, size distribution and surface charge of dried microspheres may be determined. Size characteristics are determined, for example, by dynamic light scattering technique and the surface charge was determined by measuring the zeta potential.</p><p id="p0078" num="0078">Liquid phase microcarriers include liposomes, micelles, oil droplets and other lipid or oil-based particles which incorporate biodegradable polymers or oils. In certain embodiments, the biodegradable polymer is a surfactant. In other embodiments, the liquid phase microcarriers are biodegradable due to the inclusion of a biodegradable oil such as squalene or a vegetable oil. One preferred liquid phase microcarrier is oil droplets within an oil-in-water emulsion. Preferably, oil-in-water emulsions used as microcarriers comprise biodegradable substituents such as squalene.</p><p id="p0079" num="0079">ISS/MC complexes comprise an ISS bound to the surface of a microcarrier <i>(i.e.,</i> the ISS is not encapsulated in the MC), and preferably comprise multiple molecules of ISS bound to each microcarrier. In certain embodiments, a mixture of different ISSs may be complexed with a microcarrier, such that the microcarrier is bound to more than one ISS species. The bond between the ISS and MC may be covalent or non-covalent. As will be understood by one of skill in the art, the ISS may be modified or derivatized and the composition of the microcarrier may be selected and/or modified to accommodate the desired type of binding desired for ISS/MC complex formation.</p><p id="p0080" num="0080">Covalently bonded ISS/MC complexes may be linked using any covalent crosslinking technology known in the art. Typically, the ISS portion will be modified, either to incorporate an additional moiety <i>(e.g.,</i> a free amine, carboxyl or sulfhydryl group) or incorporate modified <i>(e.g.,</i> phosphorothioate) nucleotide bases to provide a site at which the ISS portion may be linked to the microcarrier. The link between the ISS and MC portions of the complex can be made at the 3' or 5' end of the ISS, or at a suitably modified base at an internal position in the ISS. The microcarrier is generally also modified to incorporate moieties through which a covalent link may be formed, although functional groups normally present on the microcarrier may also be utilized. The ISS/MC is formed by incubating the ISS with a microcarrier under conditions which permit the formation of a covalent complex <i>(e.g.,</i> in the presence of a<!-- EPO <DP n="32"> --> crosslinking agent or by use of an activated microcarrier comprising an activated moiety which will form a covalent bond with the ISS).</p><p id="p0081" num="0081">A wide variety of crosslinking technologies are known in the art, and include crosslinkers reactive with amino, carboxyl and sulfhydryl groups. As will be apparent to one of skill in the art, the selection of a crosslinking agent and crosslinking protocol will depend on the configuration of the ISS and the microcarrier as well as the desired final configuration of the ISS/MC complex. The crosslinker may be either homobifunctional or heterobifunctional. When a homobifunctional crosslinker is used, the crosslinker exploits the same moiety on the ISS and MC (<i>e.g</i>., an aldehyde crosslinker may be used to covalently link an ISS and MC where both the ISS and MC comprise one or more free amines). Heterobifunctional crosslinkers utilize different moieties on the ISS and MC, (<i>e.g</i>., a maleimido-N-hydroxysuccinimide ester may be used to covalently link a free sulfhydryl on the ISS and a free amine on the MC), and are preferred to minimize formation of inter-microcarrier bonds. In most cases, it is preferable to crosslink through a first crosslinking moiety on the microcarrier and a second crosslinking moiety on the ISS, where the second crosslinking moiety is not present on the microcarrier. One preferred method of producing the ISS/MC complex is by 'activating' the microcarrier by incubating with a heterobifunctional crosslinking agent, then forming the ISS/MC complex by incubating the ISS and activated MC under conditions appropriate for reaction. The crosslinker may incorporate a "spacer" arm between the reactive moieties, or the two reactive moieties in the crosslinker may be directly linked.</p><p id="p0082" num="0082">In one preferred embodiment, the ISS portion comprises at least one free sulfhydryl <i>(e.g.,</i> provided by a 5'-thiol modified base or linker) for crosslinking to the microcarrier, while the microcarrier comprises free amine groups. A heterobifunctional crosslinker reactive with these two groups (<i>e.g</i>., a crosslinker comprising a maleimide group and a NHS-ester), such as succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate is used to activate the MC, then covalently crosslink the ISS to form the ISS/MC complex.</p><p id="p0083" num="0083">Non-covalent ISS/MC complexes may be linked by any non-covalent binding or interaction, including ionic (electrostatic) bonds, hydrophobic interactions, hydrogen bonds, van der Waals attractions, or a combination of two or more different interactions, as is normally the case when a binding pair is to link the ISS and MC.<!-- EPO <DP n="33"> --></p><p id="p0084" num="0084">Preferred non-covalent ISS/MC complexes are typically complexed by hydrophobic or electrostatic (ionic) interactions, or a combination thereof, (<i>e.g</i>., through base pairing between an ISS and a polynucleotide bound to an MC use of a binding pair). Due to the hydrophilic nature of the backbone of polynucleotides, ISS/MC complexes which rely on hydrophobic interactions to form the complex generally require modification of the ISS portion of the complex to incorporate a highly hydrophobic moiety. Preferably, the hydrophobic moiety is biocompatible, nonimmunogenic, and is naturally occurring in the individual for whom the composition is intended <i>(e.g.,</i> is found in mammals, particularly humans). Examples of preferred hydrophobic moieties include lipids, steroids, sterols such as cholesterol, and terpenes. The method of linking the hydrophobic moiety to the ISS will, of course, depend on the configuration of the ISS and the identity of the hydrophobic moiety. The hydrophobic moiety may be added at any convenient site in the ISS, preferably at either the 5' or 3' end; in the case of addition of a cholesterol moiety to an ISS, the cholesterol moiety is preferably added to the 5' end of the ISS, using conventional chemical reactions (see, for example, <nplcit id="ncit0177" npl-type="s"><text>Godard et al. (1995) Eur. J. Biochem. 232:404-410</text></nplcit>). Preferably, microcarriers for use in ISS/MC complexes linked by hydrophobic bonding are made from hydrophobic materials, such as oil droplets or hydrophobic polymers, although hydrophilic materials modified to incorporate hydrophobic moieties may be utilized as well. When the microcarrier is a liposome or other liquid phase microcarrier comprising a lumen, the ISS/MC complex is formed by mixing the ISS and the MC after preparation of the MC, in order to avoid encapsulation of the ISS during the MC preparation process.</p><p id="p0085" num="0085">Non-covalent ISS/MC complexes bound by electrostatic binding typically exploit the highly negative charge of the polynucleotide backbone. Accordingly, microcarriers for use in non-covalently bound ISS/MC complexes are generally positively charged (cationic) at physiological pH (<i>e.g</i>., about pH 6.8-7.4). The microcarrier may intrinsically possess a positive charge, but microcarriers made from compounds not normally possessing a positive charge may be derivatized or otherwise modified to become positively charged (cationic). For example, the polymer used to make the microcarrier may be derivatized to add positively charged groups, such as primary amines. Alternately, positively charged compounds may be incorporated in the formulation of the microcarrier during manufacture (e.g., positively charged surfactants may be<!-- EPO <DP n="34"> --> used during the manufacture of poly(lactic acid)/poly(glycolic acid) copolymers to confer a positive charge on the resulting microcarrier particles).</p><p id="p0086" num="0086">As described herein, to prepare cationic microspheres, cationic lipids or polymers, for example, 1,2-dioleoyl-1,2,3-trimethylammoniopropane (DOTAP), cetyltrimethylammonium bromide (CTAB) or polylysine, are added either to DP or CP, as per their solubility in these phases.</p><p id="p0087" num="0087">As described herein, ISS/MC complexes can be preformed by adsorption onto cationic microspheres by incubation of polynucleotide and the particles, preferably in an aqueous admixture. Such incubation may be carried out under any desired conditions, including ambient (room) temperature (e.g., approximately 20 °C) or under refrigeration (<i>e.g</i>., 4 °C). Because cationic microspheres and polynucleotides associate relatively quickly, the incubation may be for any convenient time period, such as 5, 10, 15 minutes or more, including overnight and longer incubations. For example, ISSs can be adsorbed onto the cationic microspheres by overnight aqueous incubation of polynucleotide and the particles at 4 °C. However, because cationic microspheres and polynucleotides spontaneously associate, the ISS/MC complex can be formed by sISSle co-administration of the polynucleotide and the MC. Microspheres may be characterized for size and surface charge before and after polynucleotide association. Selected batches may then evaluated for activity against suitable controls in, for example, established human peripheral blood mononuclear cell (PBMC), as described herein, and mouse splenocyte assays. The formulations may also evaluated in suitable animal models.</p><p id="p0088" num="0088">Non-covalent ISS/MC complexes linked by nucleotide base pairing may be produced using conventional methodologies. Generally, base-paired ISS/MC complexes are produced using a microcarrier comprising a bound, preferably a covalently bound, polynucleotide (the "capture polynucleotide") that is at least partially complementary to the ISS. The segment of complementarity between the ISS and the capture nucleotide is preferably at least 6, 8, 10 or 15 contiguous base pairs, more preferably at least 20 contiguous base pairs. The capture nucleotide may be bound to the MC by any method known in the art, and is preferably covalently bound to the ISS at the 5' or 3' end.<!-- EPO <DP n="35"> --></p><p id="p0089" num="0089">In other embodiments, a binding pair may be used to link the ISS and MC in an ISS/MC complex. The binding pair may be a receptor and ligand, an antibody and antigen (or epitope), or any other binding pair which binds at high affinity (e.g., Kd less than about 10-8). One type of preferred binding pair is biotin and streptavidin or biotin and avidin, which form very tight complexes. When using a binding pair to mediate ISS/MC complex binding, the ISS is derivatized, typically by a covalent linkage, with one member of the binding pair, and the MC is derivatized with the other member of the binding pair. Mixture of the two derivatized compounds results in ISS/MC complex formation.</p><p id="p0090" num="0090">Many ISS/MC complex embodiments do not include an antigen, and certain embodiments exclude antigen(s) associated with the disease or disorder which is the object of the ISS/MC complex therapy. In further embodiments, the ISS is also bound to one or more antigen molecules. Antigen may be coupled with the ISS portion of an ISS/MC complex in a variety of ways, including covalent and/or non-covalent interactions, as described, for example, in <patcit id="pcit0030" dnum="WO9816247A"><text>WO 98/16247</text></patcit>. Alternately, the antigen may be linked to the microcarrier. The link between the antigen and the ISS in ISS/MC complexes comprising an antigen bound to the ISS can be made by techniques described herein and known in the art, including, but not limited to, direct covalent linkage, covalent conjugation via a crosslinker moiety (which may include a spacer arm), noncovalent conjugation via a specific binding pair (<i>e.g</i>., biotin and avidin), and noncovalent conjugation via electrostatic or hydrophobic bonding.</p><heading id="h0014"><u>ISS complexes with cationic condensing agent and stabilizing agent</u></heading><p id="p0091" num="0091">ISSs may be administered as a composition comprising a cationic condensing agent, an ISS, and a stabilizing agent (i.e., CIS composition) for modulating an immune response in the recipient. See, <patcit id="pcit0031" dnum="US402968P"><text>U.S. Patent Application No. 60/402,968</text></patcit>. In some embodiments, the CIS composition may also comprise an antigen and/or a fatty acid.</p><p id="p0092" num="0092">The CIS compositions of the invention are typically in particulate form. As will be apparent to those of skill in the art, CIS particulate compositions of the invention will consist of a population of particles of different sizes. Due to this naturally arising variability, the "size" of the particles in the compositions of the invention may be described in ranges or as a maximum or minimum diameter. Particles are considered to be a particular size if at least 95% of the<!-- EPO <DP n="36"> --> particles (by mass) meet the specified dimension (<i>e.g</i>., if at least 97% of the particles are less than 20 µm in diameter, then the composition is considered to consist of particles of less than 20 µm in diameter). Particle size may be measured by any convenient method known in the art, including filtration (e.g., use of a "depth" filter to capture particles greater than a cutoff size), dynamic light scattering, electron microscopy, including TEM (particularly in combination with freeze-fracture processing) and SEM, and the like.</p><p id="p0093" num="0093">Preferably, the CIS compositions of the invention comprise particles which are less than about 50 µm in diameter, more preferably less than about 20 µm in diameter, although in some embodiments the particles will be less than about 3, 2 or 1 µm in diameter. Preferred particle size ranges include about 0.01 µm to 50 µm, 0.02 to 20 µm, 0.05 to 5 µm, and 0.05 to 3 µm in diameter.</p><p id="p0094" num="0094">The components of the CIS compositions may be present in various ratios/quantities in the compositions, although it is contemplated that the amounts of the stabilizing agent(s) and optional components such as fatty acids and antigen will remain relatively invariant, with stabilizing agents generally ranging from about 0.1% to 0.5% (v/v), fatty acids ranging from about 0 to 0.5%, and antigen concentrations ranging from about 0.1 to about 100 µg/mL, preferably about 1 to about 100 µg/mL, more preferably about 10 to 50 µg/mL. The amounts and ratios of the ISS and the cationic condensing agent are subject to a greater range of variation in the compositions of the invention. The amount of ISS will vary to a certain extent as a function of the molecular weight of the ISS, and generally ranges from about 50 µg/mL to about 2 mg/mL, preferably about 100 µg/mL to 1 mg/mL. The cationic condensing agent is generally present in excess (in terms of mass) over the ISS, generally in ratios of about 1:2 (ISS:cationic condensing agent) to about 1:6, more preferably about 2:5 to 1:5.</p><p id="p0095" num="0095">Particle size in the CIS compositions is a function of a number of variables. The size distribution of particles in the compositions can be modulated by altering the ratio of cationic condensing agent to ISS. For example, altering the ratio of cationic condensing agent to ISS in the exemplary +ISS/0.4% Tween 85/0.4% oleate/polymyxin B compositions can alter mean particle size from about 1.5 µm at cationic condensing agent:IMC = 1 to about 45 µm at cationic condensing agent:ISS = 10.<!-- EPO <DP n="37"> --></p><p id="p0096" num="0096">In certain embodiments, the CIS compositions comprise a cationic condensing agent, an ISS and a stabilizing agent that is a nonionic detergent. In other embodiments, the compositions comprise a membrane disrupting cationic lipopeptide (preferably a polymyxin, more preferably polymyxin B), an ISS and a stabilizing agent. In some embodiments the stabilizing agent is not a serum protein (particularly not a bovine serum protein). An exemplary composition of this class of embodiments utilizes a polyoxyethylene ether detergent such as Tween 80 or Tween 85 as the stabilizing agent, with oleate as an optional additional stabilizing agent.</p><p id="p0097" num="0097">In some embodiments, CIS compositions comprise immunomodulatory particles, wherein the particles are made by the process of combining a cationic condensing agent, an ISS and a stabilizing agent that is a nonionic detergent. In other embodiments, compositions of the invention comprise immunomodulatory particles, wherein the particles are made by the process of combining a membrane disrupting cationic lipopeptide (preferably a polymyxin, more preferably polymyxin B), an ISS and a stabilizing agent. In some embodiments, the stabilizing agent is not a serum protein (particularly not a bovine serum protein).</p><p id="p0098" num="0098">In some embodiments, CIS compositions comprise immunomodulatory particles, wherein the particles are formed by the process of combining an ISS and a stabilizing agent that is a nonionic detergent, thereby forming an ISS/stabilizing agent mixture, and combining a cationic condensing agent with the ISS/stabilizing agent mixture. In other embodiments, compositions of the invention comprise immunomodulatory particles, wherein the particles are formed by the process of combining an ISS and a stabilizing agent, thereby forming an ISS/stabilizing agent mixture, and combining a membrane disrupting cationic lipopeptide (preferably a polymyxin, more preferably polymyxin B) with the ISS/stabilizing agent mixture. In some embodiments, the stabilizing agent is not a serum protein (particularly not a bovine serum protein).</p><p id="p0099" num="0099">In some embodiments, CIS compositions comprise immunomodulatory particles, wherein the particles comprise a cationic condensing agent, an ISS and a stabilizing agent that is a nonionic detergent. In other embodiments, compositions of the invention comprise immunomodulatory particles, wherein the particles comprise a membrane disrupting cationic lipopeptide (preferably a polymyxin, more preferably polymyxin B), an ISS and a stabilizing<!-- EPO <DP n="38"> --> agent. In some embodiments, the stabilizing agent is not a serum protein (particularly not a bovine serum protein).</p><p id="p0100" num="0100">Cationic condensing agents useful in the CIS compositions and methods of using the CIS compositions are molecules which are positively charged at physiological pH (<i>i.e.,</i> pH of about 7.0 to about 7.5). Preferably, cationic condensing agents used in the instant invention are not zwitterionic and are polycationic, that is, having more than one positive charge per molecule. Cationic condensing agents useful in the instant invention include hydrophilic or amphipathic polycations.</p><p id="p0101" num="0101">Preferred cationic condensing agents include: (a) membrane disrupting cationic lipopeptides including, but not limited to polymyxins including polymyxin A, polymyxin B (including polymyxin B<sub>1</sub> and polymyxin B<sub>2</sub>), polymyxin C, polymyxin D, polymyxin E (also known as colistin), polymyxin K, polymyxin M, polymyxin P, polymyxin S and polymyxin T, circulins including circulin A, circulin B, circulin C, circulin D, circulin E and circulin F, octapeptin, amphotericins including amphotericin B, and acylated peptides including octanoyl-KFFKFFKFF and acyl KALA (octanoyl-WEAKLAKALAKALAKHLAKALAKALEACEA; (b) membrane disrupting cationic peptides including, but not limited to polymyxin B nonapeptide, cecropins including cecropin A, cecropin B and cecropin P1, KFFKFFKFF and KALA (WEAKLAKALAKALAKHLAKALAKALKACEA); (c) single chain cationic surfactants including, but not limited to cetyltrimethylammonium bromide (CTAB), benzyl-dimethyl-ammonium bromide (BDAB), CpyrB (cetyl-pyridinium bromide), CimB (cetyl imidazolium bromide), and polycationic polymers, including, but not limited to, poly-L-lysine (PLL) and polyethyleneimine (PEI). In certain embodiments, the cationic condensing agent is a membrane disrupting cationic lipopeptide, preferably a polymyxin, more preferably polymyxin B. In some embodiments, cationic condensing agents may exclude fatty acid esters (<i>i.e</i>., lipids) and double chain cationic surfactants.</p><p id="p0102" num="0102">Stabilizing agents useful in the CIS compositions and methods of using the CIS compositions include those which are suspendable in water and reduce the surface tension of water, although stabilizing agents which are water soluble and/or completely miscible in water are preferred. A number of classes of stabilizing agents are useful in the compositions and methods of the invention, including proteins (preferably hydrophilic proteins), nonionic<!-- EPO <DP n="39"> --> detergents, polymeric surfactants (<i>e.g.,</i> polyvinyl alcohol and polyvinyl pyrrolidone), cationic detergents, anionic detergents and fatty acids, although in certain embodiments, serum proteins (particularly bovine serum proteins), fatty acids, and/or ionic detergents may be excluded from the definition of stabilizing agents.</p><p id="p0103" num="0103">Any protein may be used as a stabilizing agent in accordance with the invention. In some embodiments, the stabilizing agent is a protein which is not intended as an antigen (see discussion below); in these embodiments, it is preferred that the protein be derived from the same species as the intended recipient of the composition (<i>e.g.,</i> if the composition is intended for use in humans, then it is preferred that the protein used as the stabilizing agent be a human protein). Serum albumin is an exemplary protein useful as a stabilizing agent in such embodiments. In other embodiments, an antigen is utilizing as the stabilizing agent, in which case the antigen need not be, and in general is preferably not, species matched with the intended recipient. Antigens useful in the compositions and methods of the invention are disclosed below.</p><p id="p0104" num="0104">Nonionic detergents useful in the CIS compositions and methods of using the CIS compositions include glucamides such as decyldimethylphosphine oxide (APO-10) and dimethyldodecylphosphine oxide (APO-12), octanoyl-N-methylglucamide (MEGA-8), nonanoyl-N-methylglucamide (MEGA-9) and decanoyl-N-methyl glucamide (MEGA-10), polyoxyethylene ether detergents including polyoxyethylene(10) dodecyl ester (Genapol C100), polyoxyethylene(4) lauryl ether (BRIJ® 30), polyoxyethylene(9) lauryl ether (LUBROL® PX) polyoxyethylene(23) lauryl ether (BRIJ® 35), polyoxyethylene(2) cetyl ether (BRIJ® 52), polyoxyethylene(10) cetyl ether (BRIJ® 56), polyoxyethylene(20) cetyl ether (BRIJ® 58), polyoxyethylene(2) stearyl ether (BRIJ® 72), polyoxyethylene(10) stearyl ether (BRIJ® 76), polyoxyethylene(20) stearyl ether (BRIJ® 78), polyoxyethylene(100) stearyl ether (BRIJ® 700), polyoxyethylene(2) oleyl ether (BRIJ® 92), polyoxyethylene(10) oleyl ether (BRIJ® 97), polyoxyethylene(20) oleyl ether (BRIJ® 98), isotridecylpoly(ethyleneglycolether)<sub>8</sub> (Genapol 80), PLURONIC® F-68, PLURONIC® F-127, dodecylpoly(ethyleneglycolether)<sub>9</sub> (Thesit) polyoxyethylene(10) isooctylphenyl ether (TRITON® X-100), polyoxyethylene(8) isooctylphenyl ether (TRITON® X-114), polyethylene glycol sorbitan monolaurate (TWEEN® 20), polyoxyethylenesorbitan monopalmitate (TWEEN® 40), polyethylene glycol sorbitan<!-- EPO <DP n="40"> --> monostearate (TWEEN® 60), polyoxyethylenesorbitan tristearate (TWEEN® 65), polyethylene glycol sorbitan monooleate (TWEEN® 80), polyoxyethylene(20) sorbitan trioleate (TWEEN® 85), poloxamer 188, and polyethyleneglycol-p-isooctylphenyl ether (Nonidet NP40), alkyl maltoside detergents including cyclohexyl-<i>n</i>-ethyl-β-D-maltoside, cyclohexyl-<i>n</i>-hexyl-β-D-maltoside, and cyclohexyl-<i>n</i>-methyl-β-D-maltoside, <i>n</i>-decanoylsucrose, glucopyranosides including methyl 6-O-(N-heptylcarbamoyl)-a-D-glucopyranoside (HECAMEG) and alkyl glucopyranosides such as <i>n</i>-decyl-β-D-glucopyranoside, <i>n</i>-heptyl-β-D-glucopyranoside, <i>n</i>-dodecyl-β-D-glucopyranoside, <i>n</i>-nonyl-β-D-glucopyranoside, <i>n</i>-octyl-α-D-glucopyranoside, and <i>n</i>-octyl-β-D-glucopyranoside, alkyl thioglucopyranosides including <i>n</i>-heptyl-β-D-thioglucopyranoside, alkyl maltopyranosides including <i>n</i>-decyl-β-D-maltopyranoside and <i>n</i>-octyl-β-D-maltopyranoside, <i>n</i>-decyl-β-D-thiomaltoside, digitonin, <i>n</i>-dodecanoyl sucrose, <i>n</i>-dodecyl-β-D-maltoside, heptane 1,2,3-triol, <i>n-</i>octanoyl-β-D-glucosylamine (NOGA), <i>n</i>-octanoyl sucrose, poloxamers (polyoxyethylene/polyoxypropylene block copolymers) such as poloxamer 188 and poloxamer 407, and sulfobetaines including SB-10, SB-12, and SB-14and <i>n</i>-undecyl-β-D-maltoside. Preferred stablizing agents include polyoxyethylene ether detergents, particularly polyethylene glycol sorbitan monooleate and polyoxyethylene(20) sorbitan trioleate.</p><p id="p0105" num="0105">Anionic detergents useful in the CIS compositions and methods of using the CIS compositions include caprylic acid and salts thereof, chenodeoxycholic acid and salts thereof, cholic acid and salts thereof, decanesulfonic acid and salts thereof, deoxycholic acid and salts thereof, glycodeoxycholic acid and salts thereof, lauroylsarcosine and salts thereof, n-dodecyl sulfate and salts thereof (including sodium and lithium salts), taurochenodeoxycholic acid and salts thereof, taurocholic acid and salts thereof, taurodehydrocholic acid and salts thereof, taurodeoxycholic acid and salts thereof, taurolithocholic acid and salts thereof, and tauroursodeoxycholic acid and salts thereof.</p><p id="p0106" num="0106">Cationic detergents include cetylpyridinium and salts thereof, cetyltrimethylamonia and salts thereof including cetyltrimethylammonium bromide (CTAB), dodecyltrimethylammonia and salts thereof including dedecyltrimethylammonium bromide, alklylammonium imidazolines, quaternary imidazolines, and tetradecyltrimtheylammonia and salts thereof including tetradecyltrimtheylammonium bromide.<!-- EPO <DP n="41"> --></p><p id="p0107" num="0107">Detergents selected for use as stablizing agents are preferably those that are considered oil/water emulsifying detergents. Oil/water emulsifying detergents are known in the art, and are generally characterized by a hydrophobic/lipophilic balance (HLB) value of about 8 to about 18. Preferably, detergents incorporated into the particulate compositions have HLB values of about 10 to about 16, more preferably about 11 to about 15 (<i>e.g</i>., polyethylene glycol sorbitan monooleate, HLB = 15.4; polyoxyethylene(10) isooctylphenyl ether, HLB = 13.5; polyoxyethylene(20) sorbitan trioleate HLB = 11).</p><p id="p0108" num="0108">In certain embodiments, the CIS compositions may also include one or more fatty acids, or a salt thereof, as an additional component. In those embodiments employing a fatty acid as the stablizing agent component and a fatty acid as an additional component of the composition, the fatty acid utilized as the stablizing agent will be different than the fatty acid used as the 'additional' component. Fatty acids useful in the CIS compositions of the invention may range in size from four to 30 carbon atoms, and may be unsaturated (<i>e.g.,</i> stearic acid), monounsaturated (<i>e.g</i>., oleic acid), or polyunsaturated (<i>e.g</i>., linoleic acid), although monounsaturated and polyunsaturated fatty acids are generally preferred.</p><p id="p0109" num="0109">In some embodiments, the CIS compositions will incorporate a fatty acid having a carbon chain length of at least about 4, 5, 6, 8, 10, 15, 18, or 20 carbon atoms and less than about 30, 25, 20, 19, 15 or 10 carbon atoms. Accordingly, in some embodiments, the fatty acids utilized in the invention may have carbon chains with a length in the range of about 4 to 30, 5 to 25, 10 to 20, or 15 to 20 carbon atoms.</p><p id="p0110" num="0110">Fatty acids useful in the CIS compositions include, but are not limited to, arachidonic acid, decanoic acid, docosanoic acid, docosahexanoic acid eicosanoic acid, heneicosanoic acid, heptadecanoic acid, heptanoic acid, hexanoic acid, lauric acid, linoleic acid, linolenic acid, myristic acid, nonadecanoic acid, nonanoic acid, octanoic acid, oleic acid, palmitic acid, pentadecanoic acid, stearic acid, tetracosanoic acid, tricosanoic acid, tridecanoic acid, and undecanoic acid. Preferred fatty acids for use in the CIS compositions include oleic acid palmitoleic acid, and linoleic acid.</p><p id="p0111" num="0111">In certain embodiments of the invention, an antigen is incorporated into the CIS composition or administered in combination with a CIS composition. Those CIS compositions<!-- EPO <DP n="42"> --> incorporating an antigen may incorporate the antigen into the particulate composition itself, or be dissolved or suspended in the solution in which the particulate composition is suspended. Any antigen may be incorporated into or co-administered with a CIS composition of the invention.</p><heading id="h0015"><u>Delivery of ISS</u></heading><p id="p0112" num="0112">In one embodiment, the ISS is to be delivered by itself into the individual. The ISS may be delivered with one or more antigens. The antigen may be administered with the ISS in a separate vehicle. The administration of the antigen can be contemporaneous or simultaneous with the ISS. Discussion of delivery of ISS <i>infra</i> also contemplates delivery of the antigen with the ISS.</p><p id="p0113" num="0113">The delivery of the ISS can be localized to the upper respiratory tract. As allergic rhinitis affects the nasal tract, it is contemplated that the delivery of the ISS be localized to the nasal passages and nasal region. As allergic rhinitis does not affect the lungs or lower respiratory tract, then care should be taken to avoid toxicity or any other adverse effects of administering compounds that are not necessary to treat allergic rhinitis.</p><p id="p0114" num="0114">ISS may be incorporated into a delivery vector, such as a plasmid, cosmid, virus or retrovirus, which may in turn code for therapeutically beneficial polypeptides, such as cytokines, hormones and antigens. Incorporation of ISS into such a vector does not adversely affect their activity.</p><p id="p0115" num="0115">A colloidal dispersion system may be used for targeted delivery of the ISS to an inflamed tissue, such as nasal membranes. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water The emulsions, micelles, mixed micelles, and liposomes. The colloidal system may be a liposome.</p><p id="p0116" num="0116">Liposomes are artificial membrane vesicles which are useful as delivery vehicles <i>in vitro</i> and <i>in vivo.</i> It has been shown that large unilamellar vesicles (LUV), which range in size from 0.2-4.0, um can encapsulate a substantial percentage of an aqueous buffer containing large<!-- EPO <DP n="43"> --> macromolecules. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (<nplcit id="ncit0178" npl-type="s"><text>Fraley, et al, Trends Biochem. Sci., 6:77, 1981</text></nplcit>). In addition to mammalian cells, liposomes have been used for delivery of polynucleotides in plant, yeast and bacterial cells. In order for a liposome to be an efficient gene transfer vehicle, the following characteristics should be present: (1) encapsulation of the genes encoding the antisense polynucleotides at high efficiency while not compromising their biological activity; (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4) accurate and effective expression of genetic information (<nplcit id="ncit0179" npl-type="s"><text>Mannino, et al., Biotechniques, 6:682, 1988</text></nplcit>).</p><p id="p0117" num="0117">The composition of the liposome is usually a combination of phospholipids, particularly high-phase transition-temperature phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used. The physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations.</p><p id="p0118" num="0118">Examples of lipids useful in liposome production include phosphatidyl compounds, such as phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebrosides, and gangliosides. Particularly useful are diacylphosphatidylglycerols, where the lipid moiety contains from 14-18 carbon atoms, particularly from 16-18 carbon atoms, and is saturated. Illustrative phospholipids include egg phosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.</p><p id="p0119" num="0119">The targeting of liposomes can be classified based on anatomical and mechanistic factors. Anatomical classification is based on the level of selectivity, for example, organ-specific, cell-specific, and organelle-specific. Mechanistic targeting can be distinguished based upon whether it is passive or active. Passive targeting utilizes the natural tendency of liposomes to distribute to cells of the reticulo-endothelial system (RES) in organs which contain sinusoidal capillaries. Active targeting, on the other hand, involves alteration of the liposome by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein, or by changing the composition or size of the liposome in order to achieve targeting to organs and cell types other than the naturally occurring sites of localization.<!-- EPO <DP n="44"> --></p><p id="p0120" num="0120">The surface of the targeted delivery system may be modified in a variety of ways. In the case of a liposomal targeted delivery system, lipid groups can be incorporated into the lipid bilayer of the liposome in order to maintain the targeting ligand in stable association with the liposomal bilayer. Various well known linking groups can be used for joining the lipid chains to the targeting ligand (see, e.g., <nplcit id="ncit0180" npl-type="s"><text>Yanagawa, et al., Nuc.Acids Symp.Ser., 19:189 (1988</text></nplcit>); <nplcit id="ncit0181" npl-type="s"><text>Grabarek, et al., Anal. Biochem., 185:131 (1990</text></nplcit>); <nplcit id="ncit0182" npl-type="s"><text>Staros, et al., Anal.Biochem., 156:220 (1986</text></nplcit>) and <nplcit id="ncit0183" npl-type="s"><text>Boujrad, et al., Proc. Natl. Acad. Sci. USA, 90:5728 (1993</text></nplcit>). Targeted delivery of ISS can also be achieved by conjugation of the ISS to a the surface of viral and non-viral recombinant expression vectors, to an antigen or other ligand, to a monoclonal antibody or to any molecule which has the desired binding specificity.</p><p id="p0121" num="0121">Those of ordinary skill in the art will also be familiar with, or can readily determine, methods useful in preparing oligonucleotide-peptide conjugates. Conjugation can be accomplished at either termini of the ISS or at a suitably modified base in an internal position (e.g., a cytosine or uracil). For reference, methods for conjugating oligonucleotides to proteins and to oligosaccharide moieties of Ig are known (see, e.g., <nplcit id="ncit0184" npl-type="s"><text>O'Shannessy, et al., J.Applied Biochem., 7:347 (1985</text></nplcit>). Another useful reference is <nplcit id="ncit0185" npl-type="b"><text>Kessler: "Nonradioactive Labeling Methods for Nucleic Acids", in Kricka (ed.), Nonisotopic DNA Probe Techniques (Acad. Press, 1992</text></nplcit>)).</p><p id="p0122" num="0122">Co-administration of a peptide drug with an ISS according to the invention may also be achieved by incorporating the ISS in cis or in trans into a recombinant expression vector (plasmid, cosmid, virus or retrovirus) which codes for any therapeutically beneficial protein deliverable by a recombinant expression vector. If incorporation of an ISS into an expression vector for use in practicing the invention is desired, such incorporation may be accomplished using conventional techniques which do not require detailed explanation to one of ordinary skill in the art. For review, however, those of ordinary skill may wish to consult Ausubel, <i>Current Protocols in Molecular Biology,</i> supra.</p><p id="p0123" num="0123">Briefly, construction of recombinant expression vectors (including those which do not code for any protein and are used as carriers for ISS) employs standard ligation techniques. For analysis to confirm correct sequences in vectors constructed, the ligation mixtures may be used to transform a individual cell and successful transformants selected by antibiotic resistance<!-- EPO <DP n="45"> --> where appropriate. Vectors from the transformants are prepared, analyzed by restriction and/or sequenced by, for example, the method of <nplcit id="ncit0186" npl-type="s"><text>Messing, et al., (Nucleic Acids Res., 9:309, 1981</text></nplcit>), the method of <nplcit id="ncit0187" npl-type="s"><text>Maxam, et al., (Methods in Enzymology, 65:499,1980</text></nplcit>), or other suitable methods which will be known to those skilled in the art. Size separation of cleaved fragments is performed using conventional gel electrophoresis as described, for example, by <nplcit id="ncit0188" npl-type="s"><text>Maniatis, et al., (Molecular Cloning, pp. 133-134, 1982</text></nplcit>).</p><p id="p0124" num="0124">Individual cells may be transformed with expression vectors and cultured in conventional nutrient media modified as is appropriate for inducing promoters, selecting transformants or amplifying genes. The culture conditions, such as temperature, pH and the like, are those previously used with the individual cell selected for expression, and will be apparent to the ordinarily skilled artisan.</p><p id="p0125" num="0125">If a recombinant expression vector is utilized as a carrier for the ISS of the invention, plasmids and cosmids are particularly preferred for their lack of pathogenicity. However, plasmids and cosmids are subject to degradation in vivo more quickly than viruses and therefore may not deliver an adequate dosage of ISS to substantially inhibit ISS immunostimulatory activity exerted by a systemically administered gene therapy vector. Of the viral vector alternatives, adenoassociated viruses would possess the advantage of low pathogenicity. The relatively low capacity of adeno-associated viruses for insertion of foreign genes would pose no problem in this context due to the relatively small size in which ISS of the invention can be synthesized.</p><p id="p0126" num="0126">Other viral vectors that can be utilized in the invention include adenovirus, adeno-associated virus, herpes virus, vaccinia or an RNA virus such as a retrovirus. Retroviral vectors are preferably derivatives of a marine, avian or human HIV retrovirus. Examples of retroviral vectors in which a single foreign gene can be inserted include, but are not limited to: Moloney marine leukemia virus (MoMuLV), Harvey marine sarcoma virus (HaMuSV), marine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV). A number of additional retroviral vectors can incorporate multiple genes. All of these vectors can transfer or incorporate a gene for a selectable marker so that transduced cells can be identified and generated.<!-- EPO <DP n="46"> --></p><p id="p0127" num="0127">Since recombinant retroviruses are defective, they require assistance in order to produce infectious vector particles. This assistance can be provided, for example, by using helper cell lines that contain plasmids encoding all of the structural genes of the retrovirus under the control of regulatory sequences within the LTR. These plasmids are missing a nucleotide sequence that enables the packaging mechanism to recognize an RNA transcript for encapsidation. Helper cell lines that have deletions of the packaging signal include, but are not limited to, T2, PA317 and PA 12, for example. These cell lines produce empty virions, since no genome is packaged. If a retroviral vector is introduced into such helper cells in which the packaging signal is intact, but the structural genes are replaced by other genes of interest, the vector can be packaged and vector virion can be produced. By inserting one or more sequences of interest into the viral vector, along with another gene which encodes the ligand for a receptor on a specific target cell, for example, the vector can be rendered target specific. Retroviral vectors can be made target specific by inserting, for example, a polynucleotide encoding a sugar, a glycolipid, or a protein. Preferred targeting is accomplished by using an antibody to target the retroviral vector. Those of skill in the art will know of, or can readily ascertain without undue experimentation, specific polynucleotide sequences which can be inserted into the retroviral genome to allow target specific delivery of the retroviral vector containing ISS.</p><heading id="h0016"><u>Pharmaceutical Compositions of ISS</u></heading><p id="p0128" num="0128">If the ISS is to be delivered without use of a vector or other delivery system, the ISS will be prepared in a pharmaceutically acceptable composition. Pharmaceutically acceptable carriers preferred for use with the ISS of the invention may include sterile aqueous of non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, antioxidants, chelating agents, and inert gases and<!-- EPO <DP n="47"> --> the like. A composition of ISS may also be lyophilized using means well known in the art, for subsequent reconstitution and use according to the invention.</p><p id="p0129" num="0129">Absorption promoters, detergents and chemical irritants (e.g., keritinolytic agents) can enhance transmission of an ISS composition into a target tissue. For reference concerning general principles regarding absorption promoters and detergents which have been used with success in mucosal delivery of organic and peptide-based drugs, see <nplcit id="ncit0189" npl-type="b"><text>Chien, Novel Drug Delivery Systems, Ch. 4 (Marcel Dekker, 1992</text></nplcit>).</p><p id="p0130" num="0130">Examples of suitable nasal absorption promoters in particular are set forth at Chien, supra at Ch. 5, Tables 2 and 3; milder agents are preferred. Suitable agents for use in the method of this invention for mucosal/nasal delivery are also described in <nplcit id="ncit0190" npl-type="b"><text>Chang, et al., Nasal Drug Delivery, "Treatise on Controlled Drug Delivery", Ch. 9 and Table 3-4B thereof, (Marcel Dekker, 1992</text></nplcit>). Suitable agents which are known to enhance absorption of drugs through skin are described in <nplcit id="ncit0191" npl-type="b"><text>Sloan, Use of Solubility Parameters from-Regular Solution Theory to Describe Partitioning-Driven Processes, Ch. 5, "Prodrugs: Topical and Ocular Drug Delivery" (Marcel Dekker, 1992</text></nplcit>), and at places elsewhere in the text.</p><heading id="h0017"><u>Methods and Routes for Administration of ISS to an Individual</u></heading><p id="p0131" num="0131">The ISS of the invention are administered to an individual using any available method and route suitable for drug delivery. In one embodiment, the individual is a human. In another embodiment, the individual is a human who suffers from allergic rhinitis. In another embodiment, the individual is a human who has allergic rhinitis but not asthma. In another embodiment, the individual is a human who has allergic rhinitis and allergic asthma.</p><p id="p0132" num="0132">One preferred method of delivery of ISS is intranasal delivery, as described in the Examples. Other methods of administration include <i>ex vivo</i> methods (e.g., delivery of cells incubated or transfected with an ISS) as well as systemic or localized routes. One of ordinary skill in the art will appreciate that methods and routes of delivery which direct the ISS into the individual should avoid degradation of the ISS <i>in vivo.</i></p><p id="p0133" num="0133">We describe administering the ISS along with an antigen that is present naturally in the environment (i.e., an adventitious antigen).<!-- EPO <DP n="48"> --> Adventitious allergens can be allergens that fluctuate in levels throughout the seasons. The presence of seasonal allergens may be ascertained by using various sources, for example, weather reports from weather services, news reports broadcasted by television, radio or newspaper, institutional records, and private research. An example of an adventitious antigen is ragweed, e.g., ragweed pollen allergen Antigen E (Amb a I). Other non-limiting examples of adventitious antigens are grass allergen Lol p 1 (<nplcit id="ncit0192" npl-type="s"><text>Tamborini et al. (1997) Eur. J. Biochem. 249:886-894</text></nplcit>), major dust mite allergens Der pI and Der PII (<nplcit id="ncit0193" npl-type="s"><text>Chua et al. (1988) J. Exp. Med. 167:175-182</text></nplcit>; <nplcit id="ncit0194" npl-type="s"><text>Chua et al. (1990) Int. Arch. Allergy Appl. Immunol. 91:124-129</text></nplcit>), domestic cat allergen Fel d I (<nplcit id="ncit0195" npl-type="s"><text>Rogers et al. (1993) Mol. Immunol. 30:559-568</text></nplcit>), white birch pollen Bet vl (<nplcit id="ncit0196" npl-type="s"><text>Breiteneder et al. (1989) EMBO J. 8:1935-1938</text></nplcit>), Japanese cedar allergens Cry j 1 and Cry j 2 (<nplcit id="ncit0197" npl-type="s"><text>Kingetsu et al. (2000) Immunology 99:625-629</text></nplcit>), and protein antigens from other tree pollen (<nplcit id="ncit0198" npl-type="s"><text>Elsayed et al. (1991) Scand. J. Clin. Lab. Invest. Suppl. 204:17-31</text></nplcit>). As indicated, allergens from trees are known, including allergens from birch, juniper and Japanese cedar. Preparation of protein antigens from grass pollen for <i>in vivo</i> administration has been reported. Other antigens that may be used are described above in Table 1.</p><p id="p0134" num="0134">The entrance point for many exogenous antigens into a individual is through the skin or mucosa. Thus, delivery methods and routes which target the skin (e.g., for cutaneous and subcutaneous conditions) or mucosa (e.g., for respiratory, ocular, lingual or genital conditions) will be especially useful. Those of ordinary skill in the clinical arts will be familiar with, or can readily ascertain, means for drug delivery into skin and mucosa. For review, however, exemplary methods and routes of drug delivery useful in the invention are briefly discussed below.</p><p id="p0135" num="0135">Intranasal administration means are particularly useful in addressing respiratory problems such as allergic rhinitis, respiratory inflammation, particularly inflammation mediated by antigens transmitted from the nasal passages into the trachea or bronchioli. Such means include inhalation of aerosol suspensions or insufflation of the polynucleotide compositions of the invention. Nebulizer devices suitable for delivery of polynucleotide compositions to the nasal mucosa, trachea and bronchioli are well-known in the art and will therefore not be described in detail here. Intranasal administration also includes spraying a liquid solution or powdered mixture instilled with the compositions of the invention into the nose. For general<!-- EPO <DP n="49"> --> review in regard to intranasal drug delivery, those of ordinary skill in the art may wish to consult <nplcit id="ncit0199" npl-type="b"><text>Chien, Novel Drug Delivery Systems, Ch. 5 (Marcel Dekker, 1992</text></nplcit>).</p><p id="p0136" num="0136">Dermal routes of administration, as well as subcutaneous injections, are useful in addressing allergic reactions and inflammation in the skin. Examples of means for delivering drugs to the skin are topical application of a suitable pharmaceutical preparation, transdermal transmission, injection and epidermal administration.</p><p id="p0137" num="0137">For transdermal transmission, absorption promoters or iontophoresis are suitable methods. For review regarding such methods, those of ordinary skill in the art may wish to consult Chien, supra at Ch. 7. Iontophoretic transmission may be accomplished using commercially available "patches" which deliver their product continuously via electric pulses through unbroken skin for periods of several days or more. Use of this method allows for controlled transmission of pharmaceutical compositions in relatively great concentrations, permits infusion of combination drugs and allows for contemporaneous use of an absorption promoter.</p><p id="p0138" num="0138">An exemplary patch product for use in this method is the LECTRO PATCH trademarked product of General Medical Company of Los Angeles, Calif. This product electronically maintains reservoir electrodes at neutral pH and can be adapted to provide dosages of differing concentrations, to dose continuously and/or to dose periodically. Preparation and use of the patch should be performed according to the manufacturer's printed instructions which accompany the LECTRO PATCH product.</p><p id="p0139" num="0139">Epidermal administration essentially involves mechanically or chemically irritating the outermost layer of the epidermis sufficiently to provoke an immune response to the irritant. An exemplary device for use in epidermal administration employs a multiplicity of very narrow diameter, short tynes which can be used to scratch ISS coated onto the tynes into the skin. The device included in the MONO-VACC old tuberculin test manufactured by Pasteur Merieux of Lyon, France is suitable for use in epidermal administration of ISS. Use of the device is according to the manufacturer's written instructions included with the device product.<!-- EPO <DP n="50"> --> Similar devices which may also be used in this embodiment are those which are currently used to perform allergy tests.</p><p id="p0140" num="0140">Systemic administration involves invasive or systemically absorbed topical administration of pharmaceutical preparations. Topical applications as well as intravenous and intramuscular injections are examples of common means for systemic administration of drugs.</p><heading id="h0018"><u>Dosling Parameters for ISS</u></heading><p id="p0141" num="0141">A particular advantage of the ISS of the invention is their capacity to exert anti-inflammatory and/or immunotherapeutic activity even at low dosages. Although the dosage used will vary depending on the clinical goals to be achieved, a suitable dosage range is one which is an effective amount to obtain long term disease modification. In one embodiment, the long term disease embodiment is to reduce any one of the following symptoms of allergic rhinitis: nasal symptoms (rhinorrhea, congestion, excess nasal secretion/runny nose, sneezing, itching) or non-nasal symptoms (itchy/gritty eyes, tearing, watery eyes, red or burning eyes, post-nasal drip, ear or palate itching).</p><p id="p0142" num="0142">In one aspect, the ISS is administered in at least 8 weekly doses. The dosage of ISS to be administered is about 0.001 mg/kg to about 100 mg/kg. The dosage to be administered may be 0.005 mg/kg to about 50 mg/kg. Dosage of ISS to be administered may be about 0.01 mg/kg to about 10 mg/kg. At least 9, 10, 11, or 12 doses of ISS can be administered to the individual for achieving long term disease modification.</p><p id="p0143" num="0143">The ISS is administered multiple times over a period of time. The interval between administration of dosages may be once a week. In the alternative, a slightly shorter period of time between administration of dosages may be used, for example 3, 4, 5, or 6 days in between administration of dosages. In another alternative, a longer period of time may elapse in between administration of dosages, for example every 8, 9, 10, 11, 12, 13, or 14 days. The ISS may be administered in at least 8 weekly doses at about 0.01 mg/kg to about 10 mg/kg per dose. At least 9, 10, 11, or 12 doses of ISS can be administered to the individual for achieving long term effect.<!-- EPO <DP n="51"> --></p><p id="p0144" num="0144">The ISS may be administered at dosage of about 0.01 mg/kg to about10 mg/kg and at least 8 doses are administered to the individual with about 3, 4, 5, or 6 days in between the dosages for conferring long term disease modification. The ISS can be administered at dosage of about 0.01 mg/kg to about10 mg/kg and at least 8 doses are administered to the individual with about 8, 9, 10, 11, 12, 13, or 14 days in between the dosages for conferring long term disease modification. At least 8, 9, 10, 11, or 12 doses of ISS may be administered to the individual at intervals ranging from about 3 to about 14 days in between dosages for achieving long term effect. In another embodiment, these doses of ISS are administered approximately once a week. One of skill in the art will be able to adjust the range of dosing accordingly by measuring the levels of Th2 cytokines, as exemplified in the Examples. In view of the teaching provided by this disclosure and what is generally known at the time of filing, those of ordinary skill in the clinical arts will be familiar with, or can readily ascertain, suitable parameters for administration of ISS according to the invention.</p><p id="p0145" num="0145">In this respect, it should be noted that the anti-inflammatory and immunotherapeutic activity of ISS in the invention is essentially dose-dependent. Therefore, to increase ISS potency by a magnitude of two, each single dose should be doubled in concentration. Clinically, it may be advisable to administer the ISS in a low dosage (e.g., about 0.01 mg/kg), then increase the dosage as needed to achieve the desired therapeutic goal. Based on current studies, ISS are believed to have little or no toxicity at these dosage levels.</p><heading id="h0019"><u>Kits for Use in Practicing the Methods of the Invention</u></heading><p id="p0146" num="0146">For use in the methods described above, kits are also described Such kits may include any or all of the following: ISS (unconjugated); a pharmaceutically acceptable carrier (may be pre-mixed with the ISS) or suspension base for reconstituting lyophilized ISS; additional medicaments; a sterile vial for each ISS and additional<!-- EPO <DP n="52"> --> medicament, or a single vial for mixtures thereof, devices) for use in delivering ISS to a individual; assay reagents for detecting indicia that the immunomodulatory effects sought have been achieved in treated individuals, instructions for how to and when administer the ISS and a suitable assay device.</p><p id="p0147" num="0147">Examples illustrating the practice of the invention are set forth below. The examples are for purposes of reference only and should not be construed to limit the invention.</p><heading id="h0020">EXAMPLES</heading><heading id="h0021"><u>Example 1 Inhibition of Th2-type gene induction after intranasal treatment with 1018 ISS in a mouse model for ragweed-induced allergic asthma</u></heading><p id="p0148" num="0148">One purpose of this experiment was to investigate the duration of the effect of intranasal 1018 ISS treatment on the inhibition of allergen-induced Th2-gene induction in ragweed-sensitized and challenged mice. The genes evaluated included various Th2-cytokines, chemokines, and various other molecules involved in airway inflammation. Female BALB/c mice were intraperitoneally sensitized with ragweed on Alum on day -21 and day -14. At various time points (ranging from day -7 to day 0 plus 3 hrs), groups of mice were intranasally treated with 1018 ISS or saline under light anesthesia. On day 0, all groups were challenged intranasally with either ragweed or saline. Six hrs after challenge, lungs were harvested and snap-frozen in liquid nitrogen. Total RNA was isolated and converted into cDNA. Expression of mRNA was measured in the lung cDNA samples using real-time quantitative PCR.</p><p id="p0149" num="0149">The materials used were: 1018 (lot number AGU-003, Dynavax), Ragweed (Pollen lot #16, 24QQ 56-9FD-3, extract 17 Jan 03, Dynavax), pyrogenic-free saline (Sigma). The methods used were as follows: The study was performed with 6-8 week old female BALB/c mice from Charles River (Hollister, CA). A total of 90 mice were intraperitoneally sensitized with 10 µg of ragweed on Alum on day -21 and day -14. Starting from day -7 onwards groups of 5 mice were treated intranasally with pyrogenic-free saline (50 µl) or with 1018 ISS (20µg/50µl saline) under light isofloraine anesthesia according to the schedule below.<!-- EPO <DP n="53"> -->
<tables id="tabl0002" num="0002"><table frame="all"><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="24mm"/><colspec colnum="2" colname="col2" colwidth="30mm"/><colspec colnum="3" colname="col3" colwidth="19mm"/><colspec colnum="4" colname="col4" colwidth="19mm"/><thead><row><entry align="center" valign="top"><b>sensitization</b></entry><entry align="center" valign="top"><b>day of treatment</b></entry><entry align="center" valign="top"><b>treatment</b></entry><entry align="center" valign="top"><b>challenge</b></entry></row></thead><tbody><row><entry align="center">ragweed</entry><entry align="center">-7</entry><entry align="center">saline</entry><entry align="center">saline</entry></row><row><entry align="center">ragweed</entry><entry align="center">-7</entry><entry align="center">saline</entry><entry align="center">ragweed</entry></row><row><entry align="center">ragweed</entry><entry align="center">-7</entry><entry align="center">1018 ISS</entry><entry align="center">ragweed</entry></row><row><entry align="center">ragweed</entry><entry align="center">-5</entry><entry align="center">saline</entry><entry align="center">saline</entry></row><row><entry align="center">ragweed</entry><entry align="center">-5</entry><entry align="center">saline</entry><entry align="center">ragweed</entry></row><row><entry align="center">ragweed</entry><entry align="center">-5</entry><entry align="center">1018 ISS</entry><entry align="center">ragweed</entry></row><row><entry align="center">ragweed</entry><entry align="center">-3</entry><entry align="center">saline</entry><entry align="center">saline</entry></row><row><entry align="center">ragweed</entry><entry align="center">-3</entry><entry align="center">saline</entry><entry align="center">ragweed</entry></row><row><entry align="center">ragweed</entry><entry align="center">-3</entry><entry align="center">1018 ISS</entry><entry align="center">ragweed</entry></row><row><entry align="center">ragweed</entry><entry align="center">-1</entry><entry align="center">saline</entry><entry align="center">saline</entry></row><row><entry align="center">ragweed</entry><entry align="center">-1</entry><entry align="center">saline</entry><entry align="center">ragweed</entry></row><row><entry align="center">ragweed</entry><entry align="center">-1</entry><entry align="center">1018 ISS</entry><entry align="center">ragweed</entry></row><row><entry align="center">ragweed</entry><entry align="center">0</entry><entry align="center">saline</entry><entry align="center">saline</entry></row><row><entry align="center">ragweed</entry><entry align="center">0</entry><entry align="center">saline</entry><entry align="center">ragweed</entry></row><row><entry align="center">ragweed</entry><entry align="center">0</entry><entry align="center">1018 ISS</entry><entry align="center">ragweed</entry></row><row><entry align="center">ragweed</entry><entry align="center">0 plus 3 hrs</entry><entry align="center">saline</entry><entry align="center">saline</entry></row><row><entry align="center">ragweed</entry><entry align="center">0 plus 3 hrs</entry><entry align="center">saline</entry><entry align="center">ragweed</entry></row><row><entry align="center">ragweed</entry><entry align="center">0 plus 3 hrs</entry><entry align="center">1018 ISS</entry><entry align="center">ragweed</entry></row></tbody></tgroup></table></tables></p><p id="p0150" num="0150">On day 0, all mice were challenged intranasally with either ragweed (5 µg/50 µl saline) or saline (50 µl). Six hrs after challenge, lungs were harvested, snap-frozen in liquid nitrogen, and stored at -80°C for later use. Total RNA was isolated using RNeasy mini kits (Qiagen Inc., Valencia, CA). The RNA samples were DNAse-treated (Roche Diagnostics, Mannheim, Germany) and converted into cDNA using Superscript II Rnase H-Reverse Transcriptase (Invitrogen, Rockville, MD) according to previously published methods (<nplcit id="ncit0200" npl-type="s"><text>Scheerens et al., Eur. J. of Immunology 2001, 31:1465-74</text></nplcit>).</p><p id="p0151" num="0151">In each cDNA sample, mRNA expression levels of a variety of genes were measured using real-time quantitative PCR (ABI Prism 5700, Perkin Elmer Applied Biosystems) and SYBR green (Qiagen Inc., Valencia, CA). Sense and antisense primers used for detection were developed in house and included primer sets to Th2-cytokines, chemokines, and various other molecules involved in airway inflammation. In addition to the gene of interest, in each sample the mRNA expression of a house keeping gene was measured (in this case ubiquitin). After correcting for the amount of RNA per sample, all data were calculated relative to the expression of the house keeping gene (represented as gene/ubiquitin ratio).</p><p id="p0152" num="0152"><b>Results:</b> In <figref idrefs="f0001">Figure 1</figref>, six genes essential for the development of a Th2-type airway inflammatory response are depicted and data are expressed as gene/ubiquitin ratio. The data<!-- EPO <DP n="54"> --> demonstrate that intranasal challenge with ragweed in sensitized mice upregulated mRNA expression levels of Th2-genes such as IL-4, IL-5, and IL-13 when compared to saline-challenged mice (ragweed-challenged mice denoted as RW/RW/Saline in grey bars, saline-challenged mice denoted as RW/Saline/Saline in open bars). In addition, mRNA expression levels of the chemokines TARC, MDC and eotaxin were upregulated after allergen challenge in the RW/RW/Saline mice. In contrast, in mice pretreated with 1018 ISS (denoted as RW/RW/1018 in black bars), the ragweed-induced upregulation of the various cytokines and chemokines expression levels was inhibited, however, only when 1018 ISS pretreatment was given on day -1 or on day -3, or for some genes on day -5.</p><p id="p0153" num="0153">In <figref idrefs="f0002">figure 2</figref>, gene/ubiquitin ratios are shown for GOB-5 and C2. GOB-5 and C2 (also known as FIZZ-1) are both genes that are known to be induced in the airways by IL-4. It is clear from our data that challenge with ragweed led to upregulation of both genes. In contrast, pretreatment with 1018 ISS given a few days before the challenge with ragweed inhibited the expression of these mRNAs associated with a Th2-type airway inflammation. For GOB-5, 1018 ISS treatment is effective when given on day -1 or day -3. For C2, 1018 ISS treatment is effective when given on day -3 or day -5.</p><p id="p0154" num="0154">It has been published that pretreatment with ISS inhibits allergen-induced airway eosinophilia and airway hyperresponsiveness in a mouse model for allergic asthma (<nplcit id="ncit0201" npl-type="s"><text>Broide et al., J. Immunol., 161:7054, 1998</text></nplcit>). We have shown that this inhibition correlates with ISS-induced down-regulation of Th2 and Th2-dependent gene expression levels in the airways (<nplcit id="ncit0202" npl-type="s"><text>Hessel et al. (2005) J. Exp. Med., 202(11):1563</text></nplcit>).</p><p id="p0155" num="0155">Here, we determined the duration of ISS-mediated inhibition of the allergen-induced Th2 response in the airways. As a way to establish this window of effectiveness, we measured the expression of a series of genes in the airways that are essential in or closely related to the development of Th2-type airway inflammation after allergen challenge in sensitized mice. Our data demonstrate that 1018 ISS given between one to three days before the allergen challenge is able to inhibit the majority of these genes, which results in a greatly diminished Th2 response in the airways. If 1018 ISS is given further removed from the allergen challenge <i>(i.e.,</i> earlier than day -3), we found that 1018 ISS is not able to down-regulate Th2 or Th2-dependent gene expression.<!-- EPO <DP n="55"> --></p><p id="p0156" num="0156">Thus, if one seeks to study the direct effects of ISS treatment on the airway Th2 response, it is advisable to pretreat within one to three days before the allergen challenge, whereas if one is interested in studying the long-term effects of ISS on disease modification, it is advisable to wait at least a week after ISS treatment to ensure the absence of direct ISS effects.</p><heading id="h0022"><u>Example 2 The effects of long-term intranasal treatment with 1018 ISS in a mouse model for ragweed-induced allergic asthma.</u></heading><p id="p0157" num="0157">One purpose of this set of experiments is to investigate whether long-term intranasal treatment with 1018 ISS leads to disease modification in a mouse model for ragweed-induced allergic asthma. The long-term effects of weekly intranasal treatment with 1018 ISS in ragweed-sensitized and challenged mice were investigated.</p><p id="p0158" num="0158">Mice were sensitized and subsequently challenged with an intranasal low dose of ragweed on a weekly basis. Also on a weekly basis the mice were treated intranasally with either saline or 1018 ISS. At several time points during the course of the experiment, mice were set aside to rest for a period of 2 weeks. This rest period was to ensure that the direct effects of 1018 ISS treatment had waned. At the end of the 2 weeks, these mice were re-challenged with a high dose of ragweed and the response to this allergen challenge was evaluated by ways of measuring the amount of Th2 and Th1 cytokines in the airways and by determining the amount of airway eosinophil infiltration.</p><p id="p0159" num="0159">More specifically, the materials used were: 1018 (lot number AGU-003, Dynavax); Ragweed (Pollen lot #16, 24QQ 56-9FD-3, extract 17 Jan 03, Dynavax); pyrogenic-free saline (Sigma). The methods used were as follows: The study was performed with 6-8 week old female BALB/c mice from Charles River (Hollister, CA). The mice were intraperitoneally sensitized with 15 µg of ragweed on Alum on day 0 and day 7. Starting from day 14 onwards, mice were challenged intranasally on a weekly basis with 0.5 µg ragweed or pyrogenic-free saline (50 µl) under light isofloraine anesthesia. Simultaneously, the mice were treated weekly with 1018 ISS (20µg/50µl saline) or pyrogenic-free saline (50 µl) via the intranasal route. After 1, 2, 6, and after 10 weeks of antigen challenge and ISS treatment, mice were set aside for a rest period of 2 weeks and subsequently re-challenged intranasally with 5 µg of ragweed. Twenty-four hrs later lungs were lavaged and cytokines were measured in the lavage fluid by ELISA.<!-- EPO <DP n="56"> --> The detection levels for the IL-4, IL-13, IL-10, and IFN-γ ELISA were respectively 8, 8, 8, and 23 pg/ml. Lavage fluid was spun down and the cells recovered were counted using trypan blue. The remaining cells were used to prepare a cytospin and stained with Wright-Giemsa staining. Differential cell counts were performed and the number of eosinophils was determined for each cytospin.</p><p id="p0160" num="0160">In <figref idrefs="f0003">Figure 3</figref> and <figref idrefs="f0004">4</figref>, levels of the Th2-type cytokines IL-4, IL-13 and IL-10 measured in lavage fluid (BAL fluid) are depicted in pg/ml. In addition, in <figref idrefs="f0004">Figure 4</figref> the Th1-type cytokine IFN-γ is shown. The results indicate that weekly challenges with ragweed in sensitized mice led to a robust Th2 inflammation in the airways with high levels of IL-4, IL-13, and IL-10, as well as a high number of eosinophils (shown in <figref idrefs="f0005">Figure 5</figref>). These high levels of Th2 cytokines and eosinophils were absent when ragweed-sensitized mice were challenged with saline only. When mice were challenged with ragweed and simultaneously treated with 1018 ISS, no significant differences were observed after 1, 2, or 6 weeks of ISS treatment when comparing ragweed-challenged mice treated with saline or with ISS. However, after 10 weeks of 1018 ISS treatment, the Th2 cytokine levels as well as the number of eosinophils were significantly diminished (IL-13: * p&lt;0.05; IL-4, IL-10, and eosinophils: ** p&lt;0.01), indicating that the Th2 inflammation was inhibited in those mice. Furthermore, these data show that no increased levels of IFN-γ were induced in the mice treated with 1018 ISS at any of the time points measured, indicating that 10 weekly treatments with 1018 ISS did not induce an overt Th1-type response in the airways.</p><p id="p0161" num="0161">Our experimental data described in this experiment demonstrated that ISS treatments did lead to disease modification, i.e. inhibition of the Th2 response to allergen, however, this was in our hands not accompanied by the development of an overt Th1 response in the airways. In Example 1, we determined that the direct effects of 1018 ISS on the Th2 response in the airways lasted less than a week. Therefore, in this Example, all mice were rested for at least 2 weeks after their last ISS treatment, before being re-challenged with allergen. Thus any effects seen could not be attributed direct effects of ISS treatment. The response to the re-challenge with allergen was to determine whether the airways would still develop a Th2 inflammation in response to the allergen challenge or whether they had become refractory to allergen challenge.<!-- EPO <DP n="57"> --> Our data showed that at least 10 weekly intranasal 1018 ISS treatments was needed to achieve this disease modifying effect.</p><heading id="h0023"><u>Example 3 The effects of long-term intranasal treatment with 1018 ISS in a mouse model for ragweed-induced allergic asthma</u></heading><p id="p0162" num="0162">This set of experiments was conducted to investigate whether long-term intranasal treatment with 1018 ISS conferred disease modification in a mouse model for ragweed-induced allergic asthma and to evaluate whether this disease modification persists after 1018 ISS treatment is stopped but allergen exposure is continued.</p><p id="p0163" num="0163">Mice were sensitized and subsequently challenged with an intranasal low dose of ragweed on a weekly basis. Also on a weekly basis the mice were treated intranasally with either saline or 1018 ISS. At several time points during the course of the experiment, mice were set aside to rest for a period of 2 weeks. This rest period was to ensure that the direct effects of 1018 ISS treatment had waned. At the end of the 2 weeks, these mice were re-challenged with a high dose of ragweed and the response to this allergen challenge was evaluated by ways of measuring the amount of Th2 and Th1 cytokines in the airways. The experimental groups included in this study were as follows:
<tables id="tabl0003" num="0003"><table frame="all"><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="33mm"/><colspec colnum="2" colname="col2" colwidth="29mm"/><colspec colnum="3" colname="col3" colwidth="33mm"/><thead><row><entry align="center" valign="top"><b>sensitization</b></entry><entry align="center" valign="top"><b>weekly allergen</b></entry><entry align="center" valign="top"><b>weekly treatment</b></entry></row></thead><tbody><row><entry align="center">ragweed day 0 and 7</entry><entry align="center">ragweed wk 1-25</entry><entry align="center">saline week 1-25</entry></row><row><entry align="center">ragweed day 0 and 7</entry><entry align="center">ragweed wk 1-25</entry><entry align="center">1018 ISS week 1-25</entry></row><row><entry align="center">ragweed day 0 and 7</entry><entry align="center">ragweed wk 1-25</entry><entry align="center">1018 ISS week 1-12</entry></row><row><entry align="center">ragweed day 0 and 7</entry><entry align="center">ragweed wk 1-12</entry><entry align="center">1018 ISS week 1-12</entry></row></tbody></tgroup></table></tables></p><p id="p0164" num="0164">The purpose of the mice receiving ISS treatment for 12 weeks and allergen challenges for a total of 25 weeks was to evaluate whether ISS-induced disease modification was long-lasting in the presence of continued allergen exposure.</p><p id="p0165" num="0165">More specifically, the materials used were: 1018 (lot number AGU-003, Dynavax); Ragweed (Pollen lot # 01/26/05, Dynavax ); pyrogenic-free saline (Sigma). The study was performed with 6-8 week old female BALB/c mice from Charles River (Hollister, CA). The mice were intraperitoneally sensitized with 15 µg of ragweed on Alum on day 0 and day 7. Starting from day 14 onwards, mice were challenged intranasally on a weekly basis with 0.5 µg ragweed or pyrogenic-free saline (50 µl) under light isofloraine anesthesia. Simultaneously, the<!-- EPO <DP n="58"> --> mice were treated weekly with 1018 ISS (20µg/50µl saline) or TOLAMBA (20µg/50µl saline) or pyrogenic-free saline (50 µl) via the intranasal route. After 1, 8, 12, 16, and after 25 weeks of antigen challenges and ISS treatment, mice were set aside for a rest period of 2 weeks and subsequently re-challenged intranasally with 5 µg of ragweed. Twenty-four hours later lungs were lavaged and cytokines were measured in the lavage fluid by ELISA.</p><p id="p0166" num="0166">Results: In <figref idrefs="f0006">Figure 6</figref>, levels of the Th2-type cytokines IL-4, IL-5, IL-13 and IL-10 measured in lavage fluid (BAL fluid) are depicted in pg/ml. The detection levels for the IL-4, IL-5, IL-13, IL-10, and IFN-γ ELISA were respectively 8, 8, 8, 8, and 23 pg/ml. In addition, the Th1-type cytokine IFN-γ was measured but no induction of IFN-γ above detection level was measured in any of the treatment groups. Our results show that weekly challenges with ragweed in sensitized mice led to a robust Th2 inflammation in the airways with high levels of IL-4, IL-5, IL-13, and IL-10. When mice were challenged with ragweed and simultaneously treated with 1018 ISS, no significant differences were observed after 1 week of ISS treatment when comparing ragweed-challenged mice treated with saline or with ISS. However, after 8, 12, 16, and 25 weeks of 1018 ISS treatment, the Th2 cytokine levels were significantly diminished, indicating that the allergen-induced Th2 inflammation was inhibited in the 1018 ISS-treated mice. The observation that no detectable levels of IFN-γ were induced in the mice treated with 1018 ISS at any of the time points measured indicates that 25 weekly treatments with 1018 ISS did not induce an overt Th1-type response in the airways. In groups treated for 12 weeks with 1018 ISS that subsequently continued to receive allergen challenges for another 13 weeks, the Th2 response remained inhibited, indicating that the disease modification induced by 1018 ISS is long-lasting.</p><p id="p0167" num="0167">In Example 2, we demonstrated that 10 weekly ISS treatments led to disease modification, i.e., inhibition of the Th2 response to allergen, however, this was not accompanied by the development of an overt Th1 response in the airways. The experiment described here extends this finding with the observation that disease modification is in fact already achieved after 8 weekly 1018 ISS treatments and that this disease modification persists even when allergen exposures continued for another 13 weeks.<!-- EPO <DP n="59"> --></p><heading id="h0024"><u>Example 4 ISS-conjugates</u></heading><p id="p0168" num="0168">Methods similar to Example 3 above were used except that both 1018 ISS and 1018 ISS conjugated to Amb a I (conjugate known as TOLAMBA) were used. <figref idrefs="f0007">Figure 7</figref> is a graph that depicts the results of measuring Th2-type cytokines, IL-4, IL-5, IL-10, and IL-13 in mice that have been treated with 20 µg of 1018 ISS via the intranasal route on a weekly basis for 25 weeks or 20 µg TOLAMBA via the intranasal route on a weekly basis for 25 weeks. Th2 suppression was also observed when using ISS-conjugate. Epidemiological studies have consistently shown that allergic asthma and rhinitis often coexist in the same patients (1,2). Both airway diseases share the same trends of increasing incidence (3), predisposing factors (2), and pathophysiological mechanisms following allergen encounter (4,5) and benefit from treatment with topical steroids (6). In literature successful measurement of allergic rhinitis has been described in ovalbumin-sensitized and challenged mice (7). In this study the ovalbumin challenges were given by ways of an aerosol, and thereby affecting both the lungs and nasal passages. The study referred to includes nasal lavage eosinophil counts and measurement of the thickness of the nasal mucosa.</p><heading id="h0025"><u>Example 5 The effects of long-term intranasal treatment with 1018 ISS in a mouse model for ragweed-induced allergic rhinitis</u></heading><p id="p0169" num="0169">Epidemiological studies have consistently shown that allergic asthma and rhinitis often coexist in the same patients (<nplcit id="ncit0203" npl-type="s"><text>Parikh, A. et al., Br. Med. J. (1997) 314:1392-5</text></nplcit>, and <nplcit id="ncit0204" npl-type="s"><text>Lundback B., Clin. Exp Allergy (1998) 28:3-10</text></nplcit>). Both airway diseases share the same trends of increasing incidence (<nplcit id="ncit0205" npl-type="s"><text>Aberg, N et al., Clin. Exp. Allergy (1995) 25:815-9</text></nplcit>), predisposing factors (Lundback, supra), and pathophysiological mechanisms following allergen encounter (<nplcit id="ncit0206" npl-type="s"><text>Durham, SR., Clin. Exp. Allergy (1998) 28:11-16</text></nplcit>, and <nplcit id="ncit0207" npl-type="s"><text>Chanez, P. et al., Am. J. Respir. Crit. Care Med. (1999) 159:588-95</text></nplcit>) and benefit from treatment with topical steroids (<nplcit id="ncit0208" npl-type="s"><text>Welsch, PW et al., Mayo Clin. Proc. (1987) 62:125-34</text></nplcit>). In the literature, successful measurement of allergic rhinitis has been described in ovalbumin-sensitized and challenged mice (<nplcit id="ncit0209" npl-type="s"><text>Hellings, PW et al., Clin. Exp. Allergy, (2001) 31: 782-790</text></nplcit>). In that study the ovalbumin challenges were given by ways of an aerosol, and thereby affecting both the lungs and nasal passages. That study referred to includes nasal lavage eosinophil counts and measurement of the thickness of the nasal mucosa.<!-- EPO <DP n="60"> --></p><p id="p0170" num="0170">In this Example, experiments as described in Examples 3 and 4 are repeated and nasal parameters reflective of allergic rhinitis are evaluated. The number of weekly 1018 ISS or 1018 ISS-conjugate treatments is varied as well as the length of the period in which weekly allergen exposures are continued after cessation of the 1018 ISS or 1018 ISS-conjugate treatment. Nasal parameters include eosinophil counts and IL-4, IL-5, IL-13, IL-10 and IFN-g cytokine measurements in the nasal lavage. In addition, ISS-inducible gene expression is evaluated alongside with the evaluation of gene expression levels reflective of Th2 inflammation. Histological analysis of the nasal passage and more specifically of the nasal mucosa is included.</p><p id="p0171" num="0171">With the establishment of disease modification, two questions arose: 1) Can disease modification be reversed after re-sensitizing the animals? 2) Is the disease modifying effect on the Th2 response antigen-specific? To answer these questions, mice were sensitized with ragweed, subsequently weekly challenged for 13 weeks with ragweed, and either treated or not with 1018 ISS. This was followed by a period of 4 weekly intranasal ragweed challenges. This regimen has been proven to induce disease modification in prior experiments. From there, animals either rested or went through a re-sensitizing phase with either ragweed and alum, or with ovalbumin and alum (2 intraperitoneal injections separated by a week). One week after the last injection, all mice received a final intranasal antigen challenge. A naive, age-matched control group was used to demonstrate that animals of the same age could be successfully sensitized to either ragweed or ovalbumin.</p><p id="p0172" num="0172">Results: After a 13-week treatment course with 1018 ISS in ragweed-sensitized and challenged mice, the responsiveness of the airways to a high-dose ragweed challenge is silenced. Subsequent systemic re-sensitization with ragweed or ovalbumin followed by an airway allergen challenge (with ragweed or ovalbumin respectively) does not lead to airway eosinophilia or elevated bronchoalveolar (BAL) Th2 cytokines (<figref idrefs="f0008">Figures 8</figref> &amp; <figref idrefs="f0009">9</figref> respectively). This response to re-sensitization is the same, regardless of whether re-sensitization is performed with ragweed or ovalbumin (the "same" allergen or a "different" allergen). The presence of ovalbumin-specific IgE antibodies in the serum of ISS-treated groups (<figref idrefs="f0010">Figure 10</figref>) indicates that the systemic sensitization with ovalbumin was successful. This data implies that the local environment in the airways has changed as a consequence of ISS-treatment and can prevent an allergen-induced<!-- EPO <DP n="61"> --> Th2 response to a newly introduced allergen, even if the allergen was not present during the period that the ISS treatment was given.</p></description><claims mxw-id="PCLM56985962" lang="DE" load-source="patent-office"><!-- EPO <DP n="64"> --><claim id="c-de-01-0001" num="0001"><claim-text>Unkonjugierte immunstimulatorische Sequenz (ISS) zur Verwendung bei einer Methode zur Behandlung von allergischer Rhinitis bei einem Individuum, wobei die ISS ein CpG-Motiv enthält und wobei die Methode das Verabreichen an das Individuum von wenigstens 8 Darreichungen einer wirksamen Menge der ISS umfasst, wobei die ISS in Intervallen von 3 bis 14 Tagen verabreicht wird und wobei die Verabreichung zu einer langfristigen Krankheitsmodifikation der allergischen Rhinitis durch die Verminderung oder Beseitigung eines oder mehrerer Symptome der allergische Rhinitis für einen Zeitraum von wenigstens 13 Wochen nach Verabreichung der letzten Dosis der ISS führt.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>ISS zur Verwendung gemäß Anspruch 1, wobei die ISS wenigstens 12 Mal verabreicht wird.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>ISS zur Verwendung gemäß Anspruch 1 oder Anspruch 2, wobei die vielfachen Verabreichungen auf einer wöchentlichen Basis erfolgen.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>ISS zur Verwendung gemäß Anspruch 1 oder Anspruch 2, wobei ein Zeitraum von 3 Tagen zwischen den Verabreichungen der ISS liegt.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>ISS zur Verwendung gemäß Anspruch 1 oder Anspruch 2, wobei ein Zeitraum von 14 Tagen zwischen den Verabreichungen der ISS liegt.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>ISS zur Verwendung gemäß irgendeinem der vorangehenden Ansprüche, wobei die langfristige Krankheitsmodifikation eine Abnahme der Th2-Antwort in dem Individuum ist.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>ISS zur Verwendung gemäß Anspruch 6, wobei die Abnahme der Th2-Antwort in dem Individuum eine Abnahme irgendeines der Zytokine, ausgewählt aus der Gruppe, bestehend aus IL-4, IL-5, IL-10 und IL-13, ist.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>ISS zur Verwendung gemäß irgendeinem der vorangehenden Ansprüche, wobei die ISS eine 1018 ISS ist.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>ISS zur Verwendung gemäß irgendeinem der Ansprüche 1 bis 8, wobei die ISS wenigstens eine palindrome Sequenz von wenigstens 8 Basen in der Länge, enthaltend wenigstens ein CG-Dinukleotid, umfasst und die ISS wenigstens eine TCG-Nukleotidsequenz an dem 5'-Ende des Polypeptids enthält.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>ISS zur Verwendung gemäß irgendeinem der Ansprüche 1 bis 8, wobei die ISS 5'-N<sub>x</sub>(TCG(Nq))<sub>y</sub>N<sub>w</sub>(X<sub>1</sub>X<sub>2</sub>CGX'<sub>2</sub>X'<sub>1</sub>(CG)<sub>p</sub>)<sub>z</sub> ist, worin N Nukleoside mit x = 0-3, y = 1-4, w = -2, -1, 0, 1 oder 2, p = 0 oder 1, q = 0, 1 oder 2 und z = 1-20, worin X<sub>1</sub> und X'<sub>1</sub>, X<sub>2</sub> und X'<sub>2</sub><!-- EPO <DP n="65"> --> selbstkomplementär sind und worin das 5'T der (TCG(N<sub>q</sub>))<sub>y</sub>-Sequenz 0-3 Basen vom 5'-Ende des Polynukleotids entfernt ist.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>ISS zur Verwendung gemäß irgendeinem vorangegangenen Anspruch, wobei die ISS weniger als 200 Basen in der Länge beträgt.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>ISS zur Verwendung gemäß irgendeinem vorangegangenen Anspruch, wobei die ISS Phosphorthioat-Verknüpfungen umfasst.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>ISS zur Verwendung gemäß irgendeinem vorangegangenen Anspruch, wobei die ISS in der Gegenwart eines neu hinzukommenden Allergens verabreicht wird.</claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>ISS zur Verwendung gemäß Anspruch 13, wobei das neu hinzukommende Allergen Ambrosia (Ragweed) ist.</claim-text></claim><claim id="c-de-01-0015" num="0015"><claim-text>ISS zur Verwendung gemäß Anspruch 13, wobei das Allergen ein saisonales Allergen ist.</claim-text></claim><claim id="c-de-01-0016" num="0016"><claim-text>ISS zur Verwendung gemäß irgendeinem vorangegangenen Anspruch, wobei das Individuum ein Mensch mit allergischer Rhinitis, doch nicht mit Asthma, ist.</claim-text></claim></claims><claims mxw-id="PCLM56985963" lang="EN" load-source="patent-office"><!-- EPO <DP n="62"> --><claim id="c-en-01-0001" num="0001"><claim-text>An unconjugated immunostimulatory sequence (ISS) for use in a method for treating allergic rhinitis in an individual, wherein the ISS contains a CpG motif and wherein said method comprises administering to the individual at least 8 administrations of an effective amount of said ISS, wherein the ISS are administered at intervals of 3 to 14 days, and wherein the administration results in a long term disease modification of allergic rhinitis, by the reduction or elimination of one or more allergic rhinitis symptoms for a period of at least 13 weeks following administration of the last dose of ISS.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The ISS for use according to claim 1, wherein the ISS is administered at least 12 times.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The ISS for use according to claim 1 or claim 2 wherein the multiple administrations occur on a weekly basis.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The ISS for use according to claim 1 or claim 2, wherein there is a period of 3 days between administration of ISS.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The ISS for use according to claim 1 or claim 2, wherein there is a period of 14 days between administration of ISS.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>The ISS for use according to any one of the preceding claims, wherein the long term disease modification is a decrease of Th2 response in the individual.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>The ISS for use according to claim 6 wherein the decrease of Th2 response in the<!-- EPO <DP n="63"> --> individual is a decrease of any one of the cytokines selected from group consisting of IL-4, IL-5, IL-10, and IL-13.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>The ISS for use according to any one of the preceding claims, wherein the ISS is 1018 ISS.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>The ISS for use according to any one of claims 1 to 8, wherein the ISS comprises at least one palindromic sequence of at least 8 bases in length containing at least an CG dinucleotide and the ISS contains at least one TCG nucleotide sequence at the 5' end of the polypeptide.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>The ISS for use according to any one of claims 1 to 8 wherein the ISS is 5'-N<sub>x</sub>(TCG(Nq))<sub>y</sub>N<sub>w</sub>(X<sub>1</sub>X<sub>2</sub>COX'<sub>2</sub>X'<sub>1</sub>(CG)<sub>p</sub>)<sub>z</sub>, wherein N are nucleosides with x = 0-3, y = 1-4, w = -2, -1, 0, 1 or 2, p = 0 or 1, q = 0, 1 or 2 and z = 1-20, wherein X<sub>1</sub> and X'<sub>1</sub>, X<sub>2</sub> and X'<sub>2</sub> are self-complementary, and wherein the 5' T of the (TCG(N<sub>q</sub>))<sub>y</sub> sequence is 0-3 bases from the 5' end of the polynucleotide.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>The ISS for use according to any preceding claim, wherein the ISS is less than 200 bases in length.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>The ISS for use according to any preceding claim, wherein the ISS comprises phosphorothioate linkages.</claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>The ISS for use according to any preceding claim, wherein the ISS is administered in the presence of an adventitious allergen.</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>The ISS for use according to claim 13, wherein the adventitious allergen is ragweed.</claim-text></claim><claim id="c-en-01-0015" num="0015"><claim-text>The ISS for use according to claim 13, wherein the allergen is a seasonal allergen.</claim-text></claim><claim id="c-en-01-0016" num="0016"><claim-text>The ISS for use according to any preceding claim, wherein the individual is a human with allergic rhinitis but not asthma.</claim-text></claim></claims><claims mxw-id="PCLM56985964" lang="FR" load-source="patent-office"><!-- EPO <DP n="66"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Séquence immunostimulatrice (ISS) non conjuguée destinée à être utilisée dans un procédé de traitement de la rhinite allergique chez un individu, où l'ISS contient un motif CpG et où ledit procédé consiste à administrer à l'individu au moins 8 administrations d'une quantité efficace de ladite ISS, où les ISS sont administrées à des intervalles de 3 à 14 jours, et où l'administration entraîne une modification de la maladie à long terme, la rhinite allergique, par la réduction ou l'élimination d'un ou de plusieurs symptômes de la rhinite allergique pendant une période d'au moins 13 semaines suivant l'administration de la dernière dose d'ISS.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>ISS destinée à être utilisée selon la revendication 1, où l'ISS est administrée au moins 12 fois.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>ISS destinée à être utilisée selon la revendication 1 ou la revendication 2, où les administrations multiples sont réalisées sur une base hebdomadaire.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>ISS destinée à être utilisée selon la revendication 1 ou la revendication 2, où l'on observe une période de 3 jours entre les administrations d'ISS.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>ISS destinée à être utilisée selon la revendication 1 ou la revendication 2, où l'on observe une période de 14 jours entre les administrations d'ISS.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>ISS destinée à être utilisée selon l'une quelconque des revendications précédentes, où la modification de la maladie à long terme est une réduction de la réponse Th2 chez l'individu.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>ISS destinée à être utilisée selon la revendication 6, où la réduction de la réponse Th2 chez l'individu est une réduction de l'une quelconque des cytokines sélectionnées dans le groupe consistant en l'IL-4, l'IL-5, l'IL-10, et l'IL-13.<!-- EPO <DP n="67"> --></claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>ISS destinée à être utilisée selon l'une quelconque des revendications précédentes, où l'ISS est l'ISS 1018.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>ISS destinée à être utilisée selon l'une quelconque des revendications 1 à 8, où l'ISS comprend au moins une séquence palindromique d'une longueur d'au moins 8 bases contenant au moins un dinucléotide CG et l'ISS contient au moins une séquence de nucléotides TCG à l'extrémité 5' du polypeptide.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>ISS destinée à être utilisée selon l'une quelconque des revendications 1 à 8, où l'ISS est 5'-N<sub>x</sub>(TCG(Nq))<sub>y</sub>N<sub>w</sub>(X<sub>1</sub>X<sub>2</sub>CGX'<sub>2</sub>X'<sub>1</sub>(CG)<sub>p</sub>)<sub>z</sub>, où N sont des nucléosides avec x = 0-3, y = 1-4, w = -2, -1, 0, 1 ou 2, p = 0 ou 1, q = 0, 1 ou 2 et z = 1-20, où X<sub>1</sub> et X'<sub>1</sub>, X<sub>2</sub> et X'<sub>2</sub> sont auto-complémentaires, et où le T en 5' de la séquence TCG(Nq))<sub>y</sub> est à 0-3 bases de l'extrémité 5' du polynucléotide.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>ISS destinée à être utilisée selon l'une quelconque des revendications précédentes, où l'ISS a une longueur inférieure à 200 bases.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>ISS destinée à être utilisée selon l'une quelconque des revendications précédentes, où l'ISS comprend des liaisons phosphorothioate.</claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>ISS destinée à être utilisée selon l'une quelconque des revendications précédentes, où l'ISS est administrée en présence d'un allergène fortuit.</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>ISS destinée à être utilisée selon la revendication 13, où l'allergène fortuit est l'ambroisie.</claim-text></claim><claim id="c-fr-01-0015" num="0015"><claim-text>ISS destinée à être utilisée selon la revendication 13, où l'allergène est un allergène saisonnier.</claim-text></claim><claim id="c-fr-01-0016" num="0016"><claim-text>ISS destinée à être utilisée selon l'une quelconque des revendications précédentes, où l'individu est un humain souffrant de rhinite allergique mais non d'asthme.</claim-text></claim></claims><drawings mxw-id="PDW16672315" load-source="patent-office"><!-- EPO <DP n="68"> --><figure id="f0001" num="1"><img id="if0001" file="imgf0001.tif" wi="158" he="201" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="69"> --><figure id="f0002" num="2"><img id="if0002" file="imgf0002.tif" wi="163" he="200" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="70"> --><figure id="f0003" num="3"><img id="if0003" file="imgf0003.tif" wi="165" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="71"> --><figure id="f0004" num="4"><img id="if0004" file="imgf0004.tif" wi="165" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="72"> --><figure id="f0005" num="5"><img id="if0005" file="imgf0005.tif" wi="165" he="209" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="73"> --><figure id="f0006" num="6"><img id="if0006" file="imgf0006.tif" wi="155" he="160" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="74"> --><figure id="f0007" num="7"><img id="if0007" file="imgf0007.tif" wi="153" he="155" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="75"> --><figure id="f0008" num="8"><img id="if0008" file="imgf0008.tif" wi="165" he="212" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="76"> --><figure id="f0009" num="9"><img id="if0009" file="imgf0009.tif" wi="165" he="219" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="77"> --><figure id="f0010" num="10"><img id="if0010" file="imgf0010.tif" wi="158" he="216" img-content="drawing" img-format="tif"/></figure></drawings><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
